

REVIEW ARTICLE

Regulation of cytochrome P450 (CYP) genes by nuclear receptors

Paavo HONKAKOSKI*¹ and Masahiko NEGISHI†

*Department of Pharmaceutics, University of Kuopio, P. O. Box 1627, FIN-70211 Kuopio, Finland, and †Pharmacogenetics Section, Laboratory of Reproductive and Developmental Toxicology, NIEHS, National Institutes of Health, Research Triangle Park, NC 27709, U.S.A.

Members of the nuclear-receptor superfamily mediate crucial physiological functions by regulating the synthesis of their target genes. Nuclear receptors are usually activated by ligand binding. Cytochrome P450 (CYP) isoforms often catalyse both formation and degradation of these ligands. CYPs also metabolize many exogenous compounds, some of which may act as activators of nuclear receptors and disruptors of endocrine and cellular

homeostasis. This review summarizes recent findings that indicate that major classes of CYP genes are selectively regulated by certain ligand-activated nuclear receptors, thus creating tightly controlled networks.

Key words: endobiotic metabolism, gene expression, gene transcription, ligand-activated, xenobiotic metabolism.

INTRODUCTION

Overview of the cytochrome P450 (CYP) superfamily

CYPs constitute a superfamily of haem-thiolate proteins present in prokaryotes and throughout the eukaryotes. CYPs act as mono-oxygenases, with functions ranging from the synthesis and degradation of endogenous steroid hormones, vitamins and fatty acid derivatives ('endobiotics') to the metabolism of foreign compounds such as drugs, environmental pollutants, and carcinogens ('xenobiotics') [1]. At present, 17 mammalian CYP gene families collectively encode about 60 distinct CYP forms in any given species [2], a number expected to rise by the completion of genome-wide sequencing projects. On the basis of crystal structures of bacterial P450s, molecular modelling and site-directed mutagenesis, the overall structure of mammalian membrane-bound P450 has been deduced and residues required for substrate binding, electron transfer and haem binding have been identified [3,4].

CYPs in gene families 1–4 exhibit broad, but overlapping, substrate and product specificities that may vary between corresponding forms from different species [1,5]. Their ability to metabolize a wide array of xenobiotics [6], the inducibility of many CYP forms by xenobiotics [7–9] and documented gene polymorphisms [10,11] have all contributed to an explosion of literature on CYP-dependent drug metabolism. To name just a few examples, differences in the amounts and intrinsic capacities of CYP forms to metabolize a particular drug or chemical may influence profoundly drug–drug interactions, drug or carcinogen activation and detoxification, or species differences in CYP-catalysed reactions of toxic chemicals. The CYPs in families 1–4 also metabolize endogenous compounds, including steroids and bile acids, fatty acids, prostaglandins and other eicosanoids, and retinoids [6,12–15]. They also display complex

sex-, tissue- and development-specific expression patterns which are controlled by hormones or growth factors [16], suggesting that these CYPs may have critical roles, not only in elimination of endobiotic signalling molecules, but also in their production [17]. Data from CYP gene disruptions and natural mutations support this view (see e.g. [18,19]).

Other mammalian CYPs have a prominent role in biosynthetic pathways. CYPs belonging to gene families 5 and 8A are involved in thromboxane and prostacyclin synthesis, CYPs from families 11, 17, 19, and 21 are required for steroid-hormone biosynthesis, CYPs from families 7, 8B, 24, 27, 46, and 51 catalyse reactions in the pathways leading to the biosynthesis of bile acid, vitamin D₃ and cholesterol and CYP26 is involved in retinoid metabolism [1,2]. These CYPs usually have selective substrate specificities and they are subject to tight tissue-specific and hormone-dependent regulation [20,21]. In addition, mutations in the structural genes for these CYPs underlie some common and severe inherited diseases [22,23].

Thus CYP genes are uniquely positioned (i) to respond to both endogenous and exogenous signals by changes in CYP gene expression, and (ii) to modulate the strength and duration of these signals and even to form new signalling molecules through CYP-mediated metabolism (Figure 1). These signalling molecules may then exert their function via the ligand-dependent nuclear receptors described below.

Overview of the nuclear receptor (NR) superfamily

The NR superfamily codes for transcription factors that transform extracellular and intracellular signals into cellular responses by triggering the transcription of NR target genes. NRs share significant similarity with classical steroid-hormone and thyroid-hormone receptors (TRs) in their DNA-binding domain (DBD)

Abbreviations used: AF-1 and AF-2, activation functions 1 and 2; AhR, aryl-hydrocarbon receptor; Arnt, AhR nuclear translocator; CAR, constitutively active receptor; CPF, CYP7A promoter-binding factor; CYP, cytochrome P450; DBD, DNA-binding domain; DEX, dexamethasone; DR_n, IR_n and ER_n, direct, inverted and everted repeat with *n* bp spacing; ER, oestrogen receptor; FXR, farnesoid X receptor; GH, growth hormone; GR, glucocorticoid receptor; HNF-4, hepatocyte nuclear factor 4; LBD, ligand-binding domain; LXR, liver X receptor; NFI, nuclear factor I; NR, nuclear receptor; PB, phenobarbital; PBREM, PB-responsive enhancer module; PCN, pregnenolone 16 α -carbonitrile; PPAR, peroxisome proliferator-activated receptor; PXR, pregnane X receptor; RA, retinoic acid; RAR, retinoic acid receptor; RXR, retinoid X receptor; SF-1, steroidogenic factor 1; SHP, short heterodimerization partner; TCDD, 2,3,7,8-tetrachlorodibenzo-*p*-dioxin; TR, thyroid-hormone receptor; VDR, vitamin D receptor.

¹ To whom correspondence should be addressed (e-mail paavo.honkakoski@uku.fi).




Figure 1 Relationship between NRs, their ligands and CYP enzymes

NRs (grey box) are ligand-activated transcription factors regulating (\uparrow/\downarrow) the activity of *CYP* (mid-pink box) and other genes (pale-pink box) to generate specific cellular responses to activating ligands. These ligands are formed and degraded via specific *CYP* enzymes (\dashrightarrow). The ligands may be xenobiotics, endobiotics (X, E) or their oxidation products (XO, EO).

and ligand-binding domain (LBD) [24] (Figure 2A). The superfamily also contains receptors for non-steroid ligands, such as retinoid acid, prostaglandins and fatty acids [25] and so-called 'orphan' receptors, for which no physiologically relevant activators or ligands are yet known [26]. Over 70 distinct members of NR superfamily have been identified to date [27]. Distortions in structural genes of some NRs cause certain types of leukaemia and hormone-resistance syndromes [28–30].

Response element, DBD and dimerization domains

The response element of a NR is usually composed of two half-sites related to the hexamer AGGTCA. The organization of the binding site mirrors the nature of receptor binding (Figure 2B): (i) steroid-hormone receptors bind as homodimers to palindromes with a 3 bp spacing; (ii) many other hormone and orphan receptors form heterodimers with the retinoid X receptor (RXR) and bind to repeats with variable spacing; and (iii) some receptors bind as monomers to a single AGGTCA-like site [31]. In some cases, the nucleotide identity in the half-sites, in their spacer or in the 5' extension can dramatically affect the binding specificity, affinity and/or the transactivation properties of the NR [32–34]. On the basis of crystal structures and mutagenesis of several NRs, the 70-amino-acid conserved DBD consists of two zinc-finger subdomains followed by a C-terminal extension. The amino acids around the fourth cysteine residue in the first zinc finger define the binding specificity to the response-element half-site [31,35]. The C-terminal extension is important for correct DNA binding, especially for monomeric orphan receptors and some RXR heterodimers [36,37]. The NR dimer formation is accomplished by two distinct domains, one in the DBD and the other involving helix 10 in the LBD [38–40].




Figure 2 Structural domains in NRs and their DNA-binding sites

(A) The NRs display a common modular structure consisting of a DBD (red) and an LBD (pink). Imbedded in these are the C-terminal extension (CTE) often required for correct DNA binding, and the AF-2 activation core in the extreme C-terminus. NRs show great variability in their N-terminus, which in some cases harbours an independent AF-1 activation domain. (B) The binding of NR dimer to its cognate DNA element (black) is shown. Dimerization is indicated by the overlap in the DBD and LBD domains. The currently known orientations of NR half-sites are shown by solid arrows.

Ligand-binding and activation domains

About 250 C-terminal residues constitute the LBD that also includes a region for ligand-dependent activation (activation function 2; AF-2). Currently, several crystal structures of ligand-free, agonist- or antagonist-bound LBDs are known [41]. Even though the LBD is structurally based on a similar three-layered helix fold in all NRs, the actual ligand-binding pocket shows remarkable NR- and ligand-specific variation in its size and, naturally, amino acids involved in ligand binding (e.g. [40–44]).

According to the current model of NR activation (Figure 3), ligand binding induces great structural changes in the folding of the LBD, with AF-2 being repositioned so as to form a hydrophobic patch that is accessible to common co-activators and co-integrators such as p300/CBP, SRC-1 and TIF2 [41,45,46]. Co-activators bind to ligand-bound NRs through their LXXLL repeats (e.g. [47]) and they either possess intrinsic histone acetyltransferase activity or recruit additional histone acetyltransferases that relieve suppressive effects of the chromatin to activate transcription [48]. Some, but not all, ligand-free NRs interact with co-repressors such as N-CoR and SMRT [46] to suppress gene transcription via recruitment of histone deacetylases [49]. In addition, some receptors contain a separate activation domain (AF-1) that is ligand-independent but can interact with the AF-2 region [50,51].

Regulation of NRs

The effects of an NR on target gene expression are therefore subject to regulation (and competition by other NRs) at DNA-binding-site selection, selective dimerization, binding of distinct




Figure 3 Model for gene activation and gene repression by NRs

Ligand binding or other activating processes induce the binding of the NR to the DNA element (red). The ligand-bound NR (pink ellipses) then recruits a complex of common and/or NR-specific co-activators and co-integrators (pale-grey ellipses), and turn on acetylation of histones to activate transcription. In the absence of ligands or upon antagonist binding, some, but not all, NRs bind co-repressors (mid-grey) to trigger deacetylation of histones and maintenance of chromatin structure in an inactive state.

ligands and selective co-activator assembly (Figure 3). In addition, several other transcription factors may compete for the same co-activators [45,46]. NR-mediated regulation may be complex in other ways as well. For example, multiple isoforms of NRs can be produced by multiple promoters or alternative splicing in a cell-specific manner [52,53]. Some NRs are predominantly cytoplasmic, being translocated to the nucleus only upon ligand binding [54,55]. Many NRs are phosphorylated either upon ligand binding or through cross-talk from other signalling systems [56,57].

NR REGULATION OF *CYP* GENES

Xenobiotic-, oestrogen- and retinoid-metabolizing *CYP1* forms: potentiation and suppression of AhR-dependent expression by indirect action of steroid hormones and retinoids

CYP1A1, *CYP1A2*, and *CYP1B1* can activate polycyclic hydrocarbons and arylamines to carcinogens and produce catechol oestrogens via 2- and 4-hydroxylation [6,58–60], reactions contributing to carcinogenesis. Polyaromatic hydrocarbons such as 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) induce *CYP1A* and *CYP1B* genes through binding to the aryl-hydrocarbon receptor (AhR), translocation of the ligand-bound AhR into the nucleus, and association of the AhR with its dimerization partner, AhR nuclear translocator (Arnt). The AhR·Arnt complex then binds to xenobiotic response elements and turns on the *CYP* gene transcription in a wide variety of tissues [61]. The induction can be modulated by the protein kinase C pathway [62,63].

Glucocorticoid receptor

CYP1A1 mRNA induction is potentiated 2–4-fold by dexamethasone (DEX) in hepatic and endothelial cells [64–67]. In hepatocytes, DEX acts through intron I of the *CYP1A1* gene [68], although a direct effect of the glucocorticoid receptor (GR) has not been shown [69]. In contrast, *CYP1B1* gene induction is suppressed by DEX in fibroblasts in a GR-dependent fashion. This effect is mediated by a 265 bp DNA fragment carrying the AhR response elements, but no distinguishable GR elements [70]. Modulation of *CYP1A1* and *CYP1B1* gene expression probably takes place through protein–protein interactions between the GR and other transcription factors, as described previously [71] or by competition for common co-regulators.

Oestrogen receptor (ER)

Maximal *CYP1A1* induction depends on the presence of ER α in some cell lines [72–74]. The ER α may act indirectly on cell type-specific factors, because an acute treatment with anti-oestrogens did not influence *CYP1A1* or *CYP1B1* expression in carefully selected ER α -positive cells. Both genes were induced by TCDD, regardless of the ER α status [75]. Conflicting results may stem from sequestration of other factors by the over-expressed ER α (= ‘squelching’) or from activation of ligand-free ER α by growth-factor-dependent kinases [76,77]. Cells derived from the established ER α knockout mice [78] should assist in clarification of this matter.

No oestrogen-responsive elements in the *CYP1A1* gene have been identified. A mutual competition between ER α and AhR for their DNA elements [79] has been disputed [80]. Hoivik et al. [80] also found no inhibition by oestrogen of *CYP1A1* induction in Hepa 1c1c7 or in MCF-7 cells. In contrast, a recent report indicated that ER agonists antagonized *CYP1A1* induction only in oestrogen-regulated endometrial ECC-1 and MCF-7 cells, but not in Hep3B hepatoma or in primary keratinocytes [81]. No effect of oestradiol on DNA binding by AhR nor on *CYP1B1* induction was seen, and the ER α -mediated suppression of *CYP1A1* induction was reversed by ER antagonists and by co-expression of nuclear factor I (NFI), a transcription factor interacting with both AhR and ER α [81]. AhR and ER α potentially compete for other co-regulators as well [82,83]. Such contradictory results could result from use of different cell sublines with variable (transcription) factor levels or from squelching effects. A role for ER β that can be activated by ER α ligands [84] or for ER-related receptors [85,86] should also be considered. In conclusion, ER α seems to exert its effects on *CYP1* gene expression indirectly.

Retinoid receptors

In keratinocytes, retinoic acid (RA) has been reported either to down-regulate [87,88] or up-regulate [89] *CYP1A1* gene expression. The *CYP1A1* gene harbours an unusual DR4 element that conferred a modest RA-dependent increase in reporter-gene activity [90]. In hepatocytes, retinoids had little effect on *CYP1A1* or *CYP1A2* mRNAs [91], while RXR- and RA receptor (RAR)-selective ligands decreased hepatic *CYP1A2* in intact animals [92]. The retinoid receptors involved, their possible interplay with the AhR, or the role of RA metabolism in these processes are not known. Mouse strains deficient in RAR and RXR isoforms [25] are available to address this problem and to elucidate the role of retinoids and *CYP* forms in skin physiology and carcinogenesis.

Cross-talk from AhR to NRs

The AhR and its ligands down-regulate ER-dependent gene expression in MCF-7 breast-cancer cells and in rodent oestrogen-responsive tissues [93]. Multiple mechanisms have been suggested, and probably they are cell type- and gene-specific. For example, binding of an ER α -containing complex to the cathepsin D gene promoter was abolished by AhR recognizing an overlapping site [94]. There is a potential for competition between AhR and ER α for common co-regulators [81–83]. Finally, TCDD sometimes reduced ligand and DNA binding by ER α [95,96]. *CYP1A* inducers seem to reduce ligand binding to GR and RARs and down-regulate peroxisome proliferator-activated receptor γ (PPAR γ) mRNA, leading to decreased receptor-dependent gene expression [97–100]. AhR ligands also disturb thyroid hormone homeostasis [101] and suppress several sex-specific *CYP*

mRNAs [102,103]. The nature of this general suppression of cellular functions by AhR ligands is not clear. It may reflect the limiting cellular amounts of co-activators and probably contributes to TCDD toxicity.

The disruption of *AhR* gene leads to a marked liver disease [104] and elevated hepatic levels of retinoids due to a decrease in CYP-mediated catabolism of RA [18]. Intriguingly, this defect is not due to the RA-inducible 4-hydroxylase CYP26 [18]. CYP1A enzymes are known to metabolize retinoids [105,106], and intact AhR is required for the basal expression of CYP1A2 [104]. Even though the mouse CYP1A2 does not metabolize RA [18], it may metabolize other retinoids [14], and thus the loss of CYP1A2 might contribute to retinoid accumulation in *AhR* null mice. This hypothesis could be tested in *Cyp1a2* null mice [107].

Steroid-metabolizing liver- and sex-specific CYP2A, CYP2C, CYP2D, and CYP3A forms: hepatocyte nuclear factor 4 (HNF-4) and orphan receptors contribute to basal expression and ER α governs sexual dimorphism

Members of families CYP2 and CYP3A metabolize efficiently both xenobiotics and endogenous compounds [6,7,12]. They also display complex developmental, species-dependent and sexually dimorphic patterns of regulation that may substantially differ even between closely related CYP isoforms [16]. Several P450s in this group exhibit liver-specific or liver-predominant expression driven by distinct liver-enriched transcription factors [108,109]. Intriguingly, several sex-specific and growth-hormone (GH)-dependent CYP mRNAs is suppressed by chemicals that can activate AhR or NRs [102,103,110].

HNF-4

Comparison of *CYP2A*, *CYP2C*, and *CYP2D* gene sequences indicated that many promoters contain a motif (HPF1) around –100 bp that is important for binding of HepG2-specific proteins and transcriptional activity of rabbit *CYP2C* genes [111]. The consensus HPF-1 motif (5' RRRNCAAAGKNCANYY; see Table 1) resembled the binding site for hepatocyte nuclear factor 4 (HNF-4), an liver-enriched orphan receptor that binds to DNA as a homodimer [24,112]. *In vitro* competition and antibody supershift assays, and co-transfection of HNF-4, indicated that HNF-4 was the major regulator for rabbit *CYP2C* genes in liver [113,114]. HNF-4 or HPF-1 motifs were also shown important for activation of human *CYP2C9* [115], mouse *Cyp2a4* [116], rat *CYP3A* [117,118] and mouse *Cyp2d9* genes [119].

Orphan receptors

Related rat *CYP2C7*, *CYP2C11*, *CYP2C12* and *CYP2C13* genes seem less dependent on HNF-4 [120,121]. Although HNF-4 could recognize the HPF-1-like elements in almost every *CYP2C* gene, most of the binding in rat liver nuclear extracts was not due to HNF-4; mutation of HPF-1 motifs did not significantly reduce *CYP2C* promoter activity in HepG2 cells; and co-expression of HNF-4 in non-hepatic cells had only a marginal effect on the promoter activity [120,121]. However, the sequences of virtually all rat *CYP2C* elements do not completely conform to the HPF-1 motif or HNF-4 site [111,112], but differ at critical positions [111,114]. It appears that orphan receptors such as ear-2 and ear-3 work in concert with other transcription factors to regulate the basal *CYP2C13* gene expression [120]. The same or related orphan receptors may influence *CYP3A* gene expression as well [117,118].

Even though the activities of rabbit *CYP2C* gene promoters correlated well with their HNF-4-binding affinity, they did not

correspond to CYP2C mRNA levels *in vivo* [114]. This suggests that, in addition to HNF-4, other regulators are also important. Nevertheless, the majority of the liver-specific *CYP2A*, *CYP2C*, *CYP2D* and *CYP3A* genes are regulated by HNF-4 and related orphan receptors. Small sequence variations within the binding sites may lead to distinct binding preferences and, therefore, to gene-specific regulation by various NRs.

ER

A new role for NRs in *CYP* gene transcription has recently been discovered [122]. The sex-specific transcription of *CYP2C11* and *CYP2C12* genes is regulated by sexually distinct patterns of GH secretion in the rat that can be abolished by neonatal gonadectomy or hypophysectomy [123,124]. In the male mouse, GH governs the expression pattern of *Cyp2a4* and *Cyp2d9* genes, while in the female mouse, GH has little effect [125]. The GH-elicited nuclear localization of transcription factor STAT5b in the male mouse has emerged as the major regulator of the sex-specific *CYP* gene expression [126]. The presence of a functional ER α is absolutely required for proper sex-specific expression of *Cyp2a4* and *Cyp2d9* genes in the liver [122]. Normally, STAT5b is not detectable in nuclei from female liver. Disruption of ER α leads to nuclear localization of STAT5b in females and appearance of CYP2D9 mRNA; this masculinization can be abolished by hypophysectomy. Thus ER α is probably needed for programming of the hypophysis that involves sex-dependent expression of neuronal aromatase (CYP19) [127]. The recent *Cyp19*-null mouse [128] could be useful in tackling this problem: even though ER α can be activated by mechanisms other than ligand binding [76,77], the lack of the natural ligand for ER α and ER β should shed new light on the role of oestrogen in sexual differentiation.

Steroid- and fatty acid-metabolizing CYP2B, CYP3A and CYP4A forms: inducible expression is governed by ligand-activated nuclear receptors CAR (constitutively active receptor), PXR (pregnane X receptor) and PPAR α

CYP2B genes

CYP2B is a large gene subfamily that encodes versatile catalysts of xenobiotic and steroid hydroxylation [7,129–131]. Even closely related isoforms display distinct sex- and tissue-specific regulation [132,133]. A hallmark for *CYP2B* gene regulation is the strong inducibility of some isoforms by structurally diverse xenobiotics, including industrial solvents, barbiturates, antimycotics, and pesticides [7]. These chemicals are typified by phenobarbital (PB) and they can up-regulate several hepatic enzymes involved in xenobiotic metabolism [7] and other genes as well [134]. PB induction does not require on-going protein synthesis, but it involves an okadaic acid-sensitive dephosphorylation process [135–138].

CYP2B response elements

Data from the *CYP2B2*-transgenic mice [139] and mutant rats deficient in CYP2B2 induction [140] strongly suggested that PB-responsive elements do not reside near the transcriptional start site in *CYP2B* promoters. PB-responsive primary hepatocyte cultures, *in situ* DNA injection techniques, and the availability of active and inactive derivatives of a powerful inducer, 1,4-bis-[2-(3,5-dichloropyridyloxy)]benzene [141] facilitated the discovery of PB-responsive DNA elements (PB-responsive enhancer module; PBREM). PBREM-like elements are located at around –2300 bp in rat *CYP2B2* and mouse *Cyp2b10* genes [142–144]

Table 1 Examples of interactions between *CYP* genes and nuclear receptors

Abbreviations: NSAIDs, non-steroidal anti-inflammatory drugs; MR, mineralocorticoid receptor.

<i>CYP</i> gene	<i>CYP</i> substrates/products that can serve as NR ligands	NR affected by the <i>CYP</i> substrate/product	NRs known to regulate <i>CYP</i> gene*	Response element†	NR effect‡	Cell specificity of NR action
<i>CYP1A</i>	Oestrogens, retinoids	ERs, RARs, RXRs	ER, GR RAR	Indirect DR4?	ER, GR ↑ ↓ RAR ↑ ↓	Ubiquitous Ubiquitous?
<i>CYP1B</i>	Oestrogens	ERs	ER, GR	Indirect	ER ↑ ↓, GR ↓	Ubiquitous
<i>CYP2A</i>	Androgens	AR	HNF-4	DR1	HNF-4 ↑	Hepatocytes
<i>CYP2B</i>	Xenobiotics§ Methoxychlor	Many	CAR (PXR)	DR4	CAR ↑	Hepatocytes
<i>CYP2C</i>	Androgens§, oestrogens, retinoids	AR, ER, RARs, RXRs	GR	GRE half-sites?	GR ↑	Hepatocytes?
	Xenobiotics§ NSAIDs Methoxychlor	Many	HNF-4, orphan RAR	DR1 Unknown	HNF-4 ↑, orphan ↑ ↓ RAR ↑	Hepatocytes Hepatocytes
<i>CYP2D</i>	Androgens, retinoids, fatty acid derivatives	AR, ER, RARs, RXRs PPARs				
	Xenobiotics§ Androgens, oestrogens, vitamin D ₃	Many AR, ER	ER VDR HNF-4	Indirect Unknown DR1	ER governs GH secretion VDR ↓ HNF-4 ↑	Hypophysis Hepatocytes Hepatocytes
<i>CYP3A</i>	Xenobiotics§ Methoxychlor	Many	PXR (CAR) HNF-4, orphan	DR3, ER6 DR1	PXR ↑ HNF-4 ↑, orphan ↑ ↓	Hepatocytes, intestine Hepatocytes
	Androgens, corticoids, oestrogens, pregnanes§	AR, ER, GR	GR	GRE half sites?	GR ↑	Hepatocytes?
<i>CYP4A</i>	Fatty acid derivatives	PPARs	PPAR, (orphan)	Extended DR1	PPAR ↑, orphan ↓	Hepatocytes
<i>CYP26</i>	Retinoic acid	RARs, RXRs	RAR	Unknown	RAR ↑	Ubiquitous
<i>CYP27B1</i>	Vitamin D		VDR	Unknown	VDR ↓	Kidney
<i>CYP24</i>	Vitamin D	VDR	VDR (RXR, orphan)	DR3	VDR ↑, orphan ↓	Ubiquitous
Steroidogenic CYPs	Androgens, oestrogens, corticoids, pregnanes§	AR, ER, GR, MR	SF-1, orphan	Extended monomer	SF-1 ↑, orphan ↑ and ↓	Adrenals, gonads
<i>CYP7A</i>	Precursors for steroids		CPF LXR, FXR	Extended monomer DR4	CPF ↑ LXR ↑, FXR ↓	Hepatocytes Hepatocytes
Bile-acid-forming CYPs	Oxysterols	LXR, FXR	LXR?, FXR?	Unknown		
<i>CYP51</i>	Sterols		LXR	Unknown	Unknown	

* Nuclear receptors in parentheses have a tentative role.

† Binding elements related to AGGTCA motifs (? means role of the element is tentative or not clear; indirect or unknown effects described in the text).

‡ Activating (↑), repressing (↓) or conflicting (↑ ↓) effects on *CYP* gene expression.

§ Many compounds in this class are activators of PXR, CAR or PPAR.

and at -1700 bp in human *CYP2B6* [145]. Upon exposure of liver to PB, an increase in protein binding to PBREM can be detected *in vivo* and *in vitro* [146,147]. The PBREM is organized as an NFI-binding site flanked by two DR4 motifs (5' RKG-YCANNNNAGTNSA). Sequence differences between the PB-responsive *Cyp2b10* and non-responsive *Cyp2b9* genes and transgenic studies established that both NR sites contributed to the PB response, but the NFI site was not crucial [145,147–149].

Binding factors

Co-transfections in HepG2 and 293 cells showed that, among several NRs, only the CAR [150] could activate the PBREM [147]. Mutations in NR motifs or their spacing that decreased the PB response in primary hepatocytes correlated well with loss of *in vitro* binding to NR1 probe and with decreases in CAR-dependent gene activation [147]. DNA-affinity purifications indicated that both mouse CAR and RXR were enriched on *Cyp2b10* NR1 columns by prior PB treatment of mice [147]. Importantly, the mouse PXR was not detected in these fractions (T. Sueyoshi, I. Zelko and M. Negishi, unpublished work); this can be now understood by the relative weakness of PB as an activator of the mouse PXR [151]. In mouse liver, the binding of CAR and RXR to NR1 is PB-dependent and precedes the induction of *CYP2B10* mRNA [147]. Furthermore, both CAR expression and *Cyp2b10* gene induction are liver-specific [152,153].

Activators of CAR

PBREM mediated the induction by structurally diverse chemicals ranging from methyl isobutyl ketone and pyridine to chlorpromazine and polychlorinated biphenyls, with excellent correlation with induction of endogenous *CYP2B* mRNA [145,148]. These results suggest that most, if not all, PB-type inducers converge their effects on CAR or at least on proteins binding to PBREM. Thus CAR can sense a wide spectrum of xenobiotics, and it may activate *CYP* and other genes responsible for their elimination.

Suppression of CAR by inhibitory ligands?

This inducer-dependent increase of CAR binding and activation of PBREM in hepatocytes is in contrast with inducer-independent activation of PBREM by CAR in HepG2 and 293 cells. Neither cell line can transcribe the endogenous *CYP2B6* gene in response to PB. Because co-transfected CAR can activate reporter genes without addition of ligands [150,152], one would have envisioned a mechanism to keep CAR silent in the absence of inducers *in vivo*. The identification of 3α -hydroxy, 5α -reduced androstanes as inhibitory ligands that can dissociate co-activators from CAR [154] suggested a clear-cut mechanism: inducers could either displace or prevent formation of steroids that repressed CAR. Indeed, when HepG2 cells were transfected with a CAR expression vector, the endogenous *CYP2B6* and transfected PBREM-reporter genes became activated, suppressed by 3α -androsthenol, and re-activated in 3α -androsthenol-treated cells by PB [145]. These results show that CAR is the PB-inducible regulator of *CYP2B* genes.

However, the IC_{50} for 3α -androsthenol suppression was much higher than its levels in the blood [155]. Unlike the co-expression of many NRs and their ligands [156], 3α -androsthenol is produced in testis, where CAR and *CYP2B10* mRNAs are absent [152,153]. Production of 3α -androsthenol in hepatocytes has not been demonstrated, and it is possible that the true inhibitory ligand for CAR is a related, more potent steroid. Several compounds

that deplete cellular sterols are also *CYP2B* mRNA inducers, and addition of hydroxylated cholesterol can suppress PB induction [157]. This agrees with the idea that primary hepatocytes can synthesize a sterol/steroid metabolite that attenuates PB induction of *CYP2B* genes.

Suppression of CAR by cytoplasmic localization?

An alternative mechanism to suppress CAR has recently been provided. In HepG2 cells, CAR spontaneously resides in the nucleus as shown by transfection of a green fluorescent protein-CAR fusion protein [158]. The nuclear CAR was constitutively active, and its repression by 3α -androsthenol did not affect its localization [158]. In primary hepatocytes, native CAR resided in the cytoplasm and was translocated in the nucleus only after the administration of inducers. Furthermore, the translocation and DNA binding of CAR could be inhibited by okadaic acid [158], an inhibitor of Ser/Thr protein phosphatases, at concentrations known to suppress *Cyp2b10* gene transcription [136]. These results indicate that the mechanism to induce *CYP2B* gene transcription might occur through activation of dephosphorylation-sensitive translocation of CAR. Such ligand-induced nuclear translocation has been shown for other NRs [55,159]. Hyperphosphorylation is often associated with decreased nuclear translocation of the NR [56]. In this scenario, *CYP2B* inducers would trigger the release of CAR from cytoplasmic proteins, either indirectly or through ligand binding. The latter possibility is more likely, since nuclear CAR can be activated by inducers in 3α -androsthenol-treated HepG2 cells. If the conformation of CAR that is compatible with transactivation is also required for translocation, then inhibitory ligands can still keep CAR in an inactive form in the cytoplasm.

CYP3A genes

CYP3A enzymes are very active in steroid and bile acid 6β -hydroxylation and oxidation of scores of xenobiotics [5,6,160]. Because of their wide substrate specificity and prominent expression in liver and gut, they are the most important group of enzymes involved in drug metabolism [161]. Some *CYP3A* forms display sex- and development-specific expression [16,162] and inducibility. For example, rat *CYP3A23*, rabbit *CYP3A6*, and human *CYP3A4* genes are activated by a wide variety of antibiotics, barbiturates and other drugs, glucocorticoids and anti-glucocorticoids, and pesticides in a species-specific manner [163,164].

CYP3A response elements

The DNA elements responsive to induction by DEX have been located in the proximal promoters of *CYP3A* genes, upstream of the HNF-4 binding site [117,163,165–167]. The rat *CYP3A* genes contain a DR3 (direct repeat with 3 bp spacing) motif (5' AGTTCANNNAGTTCA) at -130 bp and an ER6 (everted repeat with 6 bp spacing) motif (5' TGAACNNNNNNA-GGTCA) at -160 bp. The rabbit *CYP3A6* and the human *CYP3A* genes contain only the ER6 motif in the proximal promoter, while both DR3 and ER6 are present in a strong distal enhancer in the *CYP3A4* gene at -7.7 kbp [168]. Unusually for an NR, the same factor seems to bind both DR3 and ER6 elements, although data from Huss et al. [166] indicated that mutations that destroyed the ER6 motif but created a DR4 or DR3 motif increased the response to DEX. Studies by Blumberg et al. [169] indicated that DR3 and DR4 were preferred over DR5.

Binding factors

The cloning of the mouse PXR [170] led to the discovery that not only glucocorticoids, but also antiglucocorticoids such as pregnenolone 16 α -carbonitrile (PCN), activated the PXR, matching the profile of known CYP3A inducers. The mouse PXR could bind to and transactivate the rat *CYP3A* DR3 motif in response to natural and synthetic pregnanes [170]. Later on, the identification of human PXR/SXR/PAR-1 [151,169,171], its ability to bind to both ER6 and DR3 motifs, and their co-expression with CYP3A isoforms strongly indicated that PXR can regulate *CYP3A* genes.

PXR ligands

Both human and mouse PXR can activate reporter genes in response to many steroids, antimycotics and antibiotics. The species-specific induction of CYP3A forms by, for example, rifampicin or PCN [163] can now be explained by their ability to activate only the human or mouse PXR, respectively [151,169,171]. This selective ligand binding can be understood by relatively low amino acid conservation in the LBD between the mouse and human PXR. Therefore PXR may be a wide-specificity receptor for both steroids in general and xenobiotics, although the possibility of a potent endogenous ligand has not been ruled out.

Cross-talk to CAR and PXR

The DNA binding preferences of CAR and PXR are quite similar, so it is possible that these NRs may activate both *CYP3A* and *CYP2B* genes. CAR can transactivate the *CYP3A4* ER6 [145]. The contribution of PXR to CYP2B induction is unknown, but rat *CYP2B1* gene is inducible by PB in intestine [173], where PXR is more abundant than CAR [150,152,170].

DEX, a ligand for mouse PXR [170], can induce CYP2B forms in hepatocytes [136,174]. However, DEX does not activate CAR [147] or PBREM in primary hepatocytes, and PXR was not detected in NR1-affinity-purified fractions (P. Honkakoski, T. Sueyoshi, I. Zelko and M. Negishi, unpublished work). Apparently, CAR does not bind DEX, and PXR does not significantly bind to PBREM *in vivo*. These data agree with findings that rat *CYP2B* and *CYP3A* gene induction by PB and DEX proceed by distinct mechanisms [151,175]. Some overlap in CAR and PXR targets may exist, but the establishment of relative roles of CAR and PXR in induction of *CYP2B*, *CYP3A* and other genes *in vivo* awaits detailed studies on their DNA- and ligand-binding preferences, and ultimately, the generation of CAR- and PXR-null mice.

DEX may act on *CYP2B* genes through another site. A functional GR element has been described in the *CYP2B2* gene at -1350 bp [176], but its role in regulation of *CYP2B* genes is not known. Similarly, human *CYP3A5* and rat *CYP3A1* contain elements in their upstream regions that can bind the GR and transactivate in response to DEX [177,178]. Because DEX can synergize the induction by PB and PCN [65,179], these elements could work in concert with PXR. Another explanation for synergism could be the increase of PXR mRNA by DEX [180]. It should be borne in mind that DEX or glucocorticoids are required for expression of other *CYP* genes and for the maintenance of hepatocytes [7,65,69,136], so the DEX effects may not be gene-specific but rather depend on maintenance of the overall transcription capacity.

Thyroid hormone has been reported to suppress PB induction of *CYP2B* and *CYP3A* genes [7,181]. The actual targets are not

known, but thyroid hormone does not influence PBREM activity [182]. The effects of retinoids on *CYP2B* and *CYP3A* gene expression are inconclusive [91,92]. The 25-hydroxycholesterol that suppressed *CYP2B* induction [157] can also activate liver X receptors (LXRs) [172], which may then interfere with CAR signalling. Some orphan receptors seem to bind to the same elements as PXR [117,118]. SHP (short heterodimerization partner) is a liver-enriched NR lacking a DBD which has been reported to suppress CAR-mediated transactivation [183]. Its role in *CYP2B* gene induction has not been studied, but a specific role seems unlikely, because the promiscuousness of SHP [183,184].

CYP4A genes

CYP4A isoforms are active in ω -hydroxylation of fatty acid derivatives such as arachidonic acid, prostaglandin A, and other eicosanoids, while they have less activity towards xenobiotics [15,185]. Their expression in liver and kidney can be increased by industrially used phthalate esters, lipid-lowering fibrate drugs, and other chemicals which share the property of being peroxisome proliferators [185,186].

Binding factors

The factor activated by peroxisome proliferators is PPAR α [187]. PPAR α was characterized before the binding elements responsible for induction of *CYP4A* genes were discovered. Mice lacking PPAR α are refractory to induction of genes encoding *CYP4A* and other fatty-acid-metabolizing enzymes, peroxisome proliferation and carcinogenesis [188]. Two other PPAR isoforms (PPAR δ and PPAR γ), with distinct tissue specificities and functions, are also known [189].

Response element

The binding and activation of *CYP4A* promoter by PPAR α has been well studied in rabbit *CYP4A6* [190]. This gene harbours several PPAR sites, among which a cluster of four imperfect AGGTCA motifs at around -660 bp constitutes the major response element. The motifs 2 and 3 are organized as a typical PPAR α ·RXR DR1 element (where DR1 is a direct repeat with 1 bp spacing), similar to that in rat *CYP4A1* gene [191]. Both binding affinity and specificity of PPAR α ·RXR for the *CYP4A6* DR1 motif were improved by 5'-flanking sequences that are conserved in other PPAR-responsive genes (5' AWCTRGGN-CANAGKTCA). The extra 5' nucleotides seem to decrease the binding of RXR·RXR dimers and other NRs [192] that have affinity for the single DR1 motif [193]. With use of natural PPAR response elements, it was established that the 5' extension sequence of AWCT is crucial for PPAR α and PPAR γ binding and transactivation [34]. A less strict dependence on the 5' extension was found in a PCR-based binding-site-selection study [194]. The similarity of PPAR response elements to the binding sites of monomeric NRs [36] indicates that the C-terminal extension of the PPAR α DBD can discriminate among different response elements to generate a specific cellular response [37].

PPAR ligands

In addition to peroxisome proliferators, endogenous compounds such as fatty acids, leukotriene B₄ and 8(*S*)-hydroxyeicosatetraenoic acid bind to PPAR α [195-197]. The ligand specificity of PPAR isoforms seems to be distinct, but overlapping, e.g. several prostaglandins activate all PPARs [197], PPAR α and

PPAR δ isoforms are activated by fatty acids [198], and non-steroidal anti-inflammatory drugs prefer PPAR α and PPAR γ [199]. Species-specific ligand binding for PPAR α has been described as well [200,201]. This broad ligand specificity of PPARs can now be understood by the large ligand-binding pocket and unique ligand access cleft in PPAR γ [44]. It is again possible that the function of PPAR α is to sense a wide spectrum of low-affinity ligands.

Cross-talk to PPAR α

The PPAR α -dependent expression is also subject to cross-talk by other NRs expressed in liver such as TAK1, LXR, TR and PPAR δ [202–205] and possibly by other DR1-recognizing receptors such as ARP-1 and HNF-4 [193]. The mechanisms seem to involve competition for both binding sites and common co-activators and 'inactive' heterodimer formation. *In vivo* induction of *CYP4A2* gene was suppressed by physiological levels of thyroid hormone, while that of *CYP4A1* and *CYP4A3* required higher doses [206].

The co-expression of *CYP4A* genes and PPAR α [190] and data from PPAR α -null mice [207] indicate that other PPAR isoforms do not regulate *CYP4A* genes in the liver. However, there is some PPAR α -independent expression of *CYP4A* genes in PPAR α -null mice [208]. Both PPAR α and PPAR γ are able to activate the *CYP4A6* promoter in transient transfections [209]. Thus it is conceivable that other PPAR isoforms may regulate other *CYP4A* genes with similar binding sites as well. *CYP4A* substrates often are PPAR ligands [189], so it is not unreasonable to look for PPAR-dependent *CYP4A* (or other *CYP*) genes in tissues involved in lipid metabolism.

Retinoid-metabolizing CYP forms: synthesis by CYP1A and retinoid-inducible catabolism by CYP26 and CYP2C7

Retinoids are a group of vitamin A derivatives that have profound effects on cell growth and differentiation [25,210]. They utilize two distinct NR signalling pathways, the RARs and the RXRs, which bind to DR2/DR5 and DR1 response elements respectively. RARs and RXRs are thought to be activated by all-*trans*-RA and 9-*cis*-RA respectively [31], although additional ligands are being found.

Formation of retinoids

RAs are synthesized from vitamin A by sequential reactions involving alcohol dehydrogenases or short-chain dehydrogenases, aldehyde dehydrogenases and several CYP isoforms [14]. CYP2B and CYP2C isoforms primarily convert retinoids into presumably inactive 4-hydroxy derivatives while rabbit CYP1A forms can catalyse both RA formation and 4-hydroxylation [105,106,211]. CYP2J4 also produces RA [212]. Novel 4-oxo acid and aldehyde derivatives are also powerful and abundant RAR ligands [213,214], and they may be produced by CYP1A2 [106].

Catabolism of retinoids

A novel RA 4-hydroxylase gene, *CYP26*, is highly expressed in liver and brain and present in several cell lines [215,216]. *CYP26* mRNA is induced by RA via action of RAR γ ·RXR α heterodimers through as-yet-undefined DNA elements [217]. Because of its RA-dependent regulation and wide expression, *CYP26* is thought to control the level and the activity of RA [215,217]. However, this form is highly specific to all-*trans*-RA, so elim-

ination of other active retinoids requires the action of other CYP enzymes. This view is supported by the fact that the presence of *CYP26* cannot prevent accumulation of retinoids in *AhR*-null mice [18]. Of interest are the known RA and retinol 4-hydroxylases, rat *CYP2C7* and human *CYP2C8* [211,218,219]. Rat *CYP2C7* gene is down-regulated by vitamin A deficiency and up-regulated by retinoids through the RAR pathway [220,221]. Intriguingly, all-*trans*-RA-dependent induction could be abolished by the CYP inhibitor ketoconazole, and 4-oxo-RA was an inducer of *CYP2C7* mRNA [221]. This controlled regulation by retinoids suggests a special role for *CYP2C7* in hepatic retinoid metabolism. The site of RAR action and its potential interplay with HNF-4 and orphan receptors [120] on *CYP2C7* promoter are yet not known.

Vitamin D-metabolizing CYP forms: synthesis by CYP27A1 and CYP2D25, and vitamin D-inducible catabolism by CYP24

Vitamin D is a precursor for biologically active 1 α ,25-dihydroxyvitamin D $_3$, which has a central role in regulation of calcium homeostasis and cell differentiation [21,222]. The 1 α ,25-dihydroxyvitamin D $_3$ binds to the vitamin D receptor (VDR), VDR·RXR heterodimer then binds to DR3 elements present in target genes and it activates their transcription via AF-2- and co-activator-dependent mechanisms [223,224]. Some VDR targets such as genes for parathyroid hormone and *CYP27B1* are down-regulated, but the ability of VDR to bind co-repressors or to interfere with positively acting transcription factors is not yet resolved [21,225]. Formation of VDR homodimers and interplay with thyroid-hormone signalling has been suggested [226], but their physiological role has not yet been established. With respect to CYP forms not involved in vitamin D metabolism, *CYP3A4* mRNA is induced by 1 α ,25-dihydroxyvitamin D $_3$ in Caco-2 cells [227], although the direct binding of VDR to the *CYP3A4* promoter or its DR3 element have not been established.

Formation of 1 α ,25-dihydroxyvitamin D $_3$

1 α ,25-Dihydroxyvitamin D $_3$ is formed by 25-hydroxylation in liver and 1 α -hydroxylation in kidney. The first reaction can be catalysed by CYP27A1, the mitochondrial sterol 27-hydroxylase [228,229]. Biochemical studies and evidence from CYP27-deficient patients suggested that another microsomal CYP form is the physiologically more important 25-hydroxylase [21]. This was supported by the fact that *CYP27A1*-null mice have normal plasma levels of 1 α ,25-dihydroxyvitamin D $_3$ [230]. The cloning of the microsomal 25-hydroxylase rather unexpectedly indicated that this form is CYP2D25 [231]. This emphasizes again that CYPs in families 1–4 have important physiological functions. The 25-hydroxylation can be suppressed by 1 α ,25-dihydroxyvitamin D $_3$ by an unknown mechanism [232].

1 α -Hydroxylation is catalysed by renal CYP27B1 which is down-regulated by 1 α ,25-dihydroxyvitamin D $_3$ and tightly regulated by other factors [21,233]. The down-regulation does not take place in *VDR*-null mice [233]. No distinct VDR response elements in *CYP27B1* genes have yet been identified. The mouse *CYP27B1* –1.7 kbp promoter was unresponsive [234], while elements within the –1100 bp of the human *CYP27B1* gene mediated activation by parathyroid hormone that was reduced by 1 α ,25-dihydroxyvitamin D $_3$ [235,236].

Catabolism of 1 α ,25-dihydroxyvitamin D $_3$

The mitochondrial 1 α ,25-dihydroxyvitamin D $_3$ 24-hydroxylase, *CYP24* is a well-characterized vitamin D target gene [237].

CYP24 inactivates vitamin D to calcitroic acid [238]. The critical role for *CYP24* in vitamin D catabolism was proved by generation of *Cyp24*-null mice which exhibited hypercalcaemia and abnormal bone histology [21,239]. The *CYP24* gene is expressed in many vitamin D target tissues, and it is up-regulated by its substrate through VDR·RXR-dependent binding to two conserved response elements at about -300 bp and at -150 bp [240,241]. Retinoids can increase *CYP24* gene expression by RAR·RXR binding to VDR response elements [242]. The orphan receptor TR4 which is co-expressed with VDR can down-regulate *CYP24* expression [243].

Steroidogenic CYP forms: complex tissue-specific and cAMP-inducible expression is controlled by steroidogenic factor 1 (SF-1) and gene-specific regulators

Steroid hormones are important endocrine factors that regulate sexual differentiation and maintenance, ion balance and carbohydrate and lipid metabolism. Steroid hormones act through their classical ligand-activated receptors, which in turn modify the expression of their target genes [24].

Tissue-specific expression

Steroid hormones are produced from cholesterol via the action of six CYP enzymes (*CYP11A*, *CYP11B1*, *CYP11B2*, *CYP17*, *CYP19*, *CYP21*), aided by 3β - and 17β -hydroxysteroid dehydrogenases [244]. These CYPs are expressed in a cell-specific manner. For example, adrenal cortex that produces gluco- and mineralocorticoids, but not oestrogen, expresses all but the *CYP19* gene, and oestrogen-forming ovary expresses *CYP11A*, *CYP17* and *CYP19* genes [20,244]. Also brain, adipose tissue, placenta and some fetal tissues express selected steroidogenic CYPs, probably reflecting a local requirement for hormones [244–246].

The expression pattern of *CYP* genes correlates with that of the SF-1 [247,248]. SF-1 is an orphan receptor that binds to extended AGGTCA-like half sites (5' YCAAGGYC or RRAGGTCA) present in all steroidogenic *CYP* proximal promoters [247,249]. Mutation of these SF-1 binding sites can decrease the *CYP* promoter activity in cells of adrenal or gonadal origin [32,250–254]. SF-1 also directs the organogenesis of adrenals and gonads, because *SF-1*-null mice lack these organs [247,255]. Oxysterols were found to activate the SF-1 [256], but their role in physiological regulation of CYPs has been questioned [257,258]. SF-1 activates genes through AF-2 [259] and p300/CBP co-regulators [260].

SF-1 is not the sole cell-specific regulator of steroidogenic *CYP* genes, because adrenals or gonads that express SF-1 lack *CYP19* or *CYP21* and *CYP11B* mRNAs respectively. This idea is reinforced by findings that *CYP11A* mRNA is present in placenta, skin, and hindgut of *SF-1*-null fetuses [246,261] and that mRNAs for several CYPs, but not SF-1, are detectable in several brain regions [245]. Contribution of other NRs that have affinity for SF-1 binding sites [32,85,262,263] or unrelated factors [264,265] requires further studies.

Cyclic AMP-induced expression

The steroidogenic *CYP* genes are positively regulated in response to trophic peptide hormones through activation of cAMP pathway [266]. Several studies have indicated SF-1 as one cAMP target for *CYP11B1*, *CYP11A*, *CYP17* and *CYP19* genes [250,252,253,259,267,268]. However, SF-1 confers only a partial cAMP response, indicating a need for other transcription factors [250,268] such as Sp1 [253,260,269]. For example, corticotropin

(ACTH) induces binding of another orphan receptor that binds to the SF-1 site at -65 bp, resulting in increased *CYP21* gene transcription [32]. Other regions of the *CYP21* gene seem to contribute to the cAMP response [270]. Loss of trophic hormones down-regulates steroidogenic CYP levels without affecting SF-1 [271]. Recently, phosphorylation of SF-1 by mitogen-activated kinases was suggested to confer maximal transactivation [51]. There is no clear evidence for increased up-regulation or phosphorylation of SF-1 in response to trophic hormones, with the possible exception of *CYP19* regulation [267,268]. Therefore cAMP-dependent regulation probably requires factors unique to each steroidogenic *CYP* gene.

Cholesterol-metabolizing CYP forms: bile acid synthesis is controlled by ligand-activated LXR, farnesoid X receptor (FXR) and a liver-specific receptor

Cholesterol synthesis and CYP51

The metabolism of cholesterol is regulated at the biosynthetic pathway by oxysterols that prevent activation of SREBP family of regulators [272]. The biosynthetic pathway involves only one CYP enzyme, the lanosterol 14α -demethylase *CYP51* [273]. *CYP51* produces so-called meiosis-activating sterols [274] that can activate *LXR α* [275] and possibly the ubiquitously expressed *LXR β* [172] as well. The human *CYP51* mRNA was suppressed by oxysterols in HepG2 and adrenal cells [276], while the rat *CYP51* was induced by gonadotropin in the ovary [277], reminiscent of steroidogenic CYP regulation. Both mechanisms are currently unknown, but may involve NRs.

Cholesterol disposal, CYP7A and CYP7B

The level of cholesterol is controlled also by catabolism to bile acids [278]. Bile acids are formed from cholesterol via two routes. The first is the liver-specific 7α -hydroxylation catalysed by *CYP7A* [279] which is down-regulated by the ultimate product chenodeoxycholic acid and activated by dietary cholesterol [278,280]. The second route involves *CYP7B*, the oxysterol 7α -hydroxylase that is expressed predominantly in brain and liver [281,282]. The substrates for *CYP7B* can be produced at least by sterol 27 -hydroxylase *CYP27A1* [228,229], a brain-specific $24(S)$ -hydroxylase *CYP46* [283] and a non-CYP cholesterol 25 -hydroxylase [284].

The up-regulation of *CYP7A* activity by excess cholesterol involves the liver-predominant *LXR α* receptor. *LXR α* could be activated by several oxysterols, including the $24(S)$ -OH derivative [275]. *LXR α* could bind to, and activate, the *CYP7A* promoter via the DR4 motif at -74 bp, while the related *LXR β* was not able to bind to DR4 well [285]. The DR4 motif is contained within the proximal of the two elements crucial for the bile acid response [286]. These findings were confirmed by the report that *LXR α* -null mice could not up-regulate their *Cyp7a* gene when challenged with high dietary cholesterol levels [287].

The tight liver-specificity of *CYP7A* gene expression cannot be determined by *LXR α* alone. A liver-specific nuclear receptor, *CYP7A*-promoter-binding factor (CPF) [288], was shown to bind and activate the *CYP7A* promoter. The monomeric AGGTCA-like binding site at -136 bp for CPF is contained within the second of the bile acid response elements identified by the Chiang group [286,288]. This suggests that both CPF and *LXR α* are needed for *CYP7A* gene regulation. Interestingly, CPF is very similar to SF-1 [247,288]. Because some oxysterols can activate SF-1 [256], it is conceivable that CPF and *LXR α* regulate *CYP7A* gene expression in parallel in response to oxysterols.

The third part of *CYP7A* regulation, the suppression by bile acids, is also being unravelled. First, the disruption of the *Cyp27a* gene and subsequent decrease in bile acid synthesis leads to a compensatory up-regulation of *CYP7A* mRNA [230]. Secondly, bile acids such as chenodeoxycholic acid have now been established as ligands for FXR [289,290], an NR expressed mainly in liver and kidney [33,291]. The ligand-bound FXR will suppress the *CYP7A* gene, as expected from *in vivo* studies. On the other hand, it can activate the gene for bile-acid-binding protein [292] or reporter genes driven by heterologous promoters [290]. LXR α -mediated transcription from the original LXR DR4 motif [33] can be repressed by ligand-bound FXR [290], suggesting a direct communication between the two receptors. It is not yet known by which mechanism the FXR-mediated suppression occurs. FXR could interfere also with CPF [288] or with other NRs potentially binding to *CYP7A* promoter [293], although the role of the latter proteins in *CYP7A* gene expression is disputable.

Oxysterol-forming CYP27A1 and CYP46 forms

CYP27A1 catalyses several hydroxylation reactions on the cholesterol side chain [228,229,294]. The regulation of this form has not been studied in detail, but rabbit CYP27A1 was up-regulated by cholesterol [295], while the effects of bile acids point towards down-regulation [296,297]. The function of CYP46 is the removal of extra cholesterol from the brain [298] via production of the 24(*S*)-OH derivative [283]. The presence of LXR β in the brain and its activation by the 24(*S*)-OH cholesterol suggest a potential activation mechanism for *CYP46* gene that remains to be tested.

Bile acid-forming CYP8B and other CYP forms

CYP8B constitutes a further step in bile acid synthesis by catalysing liver-specific 12 α -hydroxylation [278]. CYP8B mRNA is suppressed at the pretranslational level by thyroid hormone [299] and up-regulated by bile acid sequestration, concomitant with CYP7A mRNA increase [300]. Further metabolism of bile acids by side-chain and 6 β -hydroxylation are catalysed by CYP3A and CYP2B enzymes [131,160] that are regulated by PXR and CAR. The above reports suggest that similar NR-dependent mechanisms that control *CYP7A* gene expression may also regulate other enzymes involved in cholesterol and bile acid metabolism. Results testing this hypothesis should be forthcoming.

CONCLUSIONS

Feedback regulation

As detailed in previous sections, the *CYP* genes and nuclear receptors form a complex network that may involve feedback regulation (see Figure 1 and Table 1). First, several CYPs degrade ligands that activate the NR responsible for regulation of this specific CYP form, thus creating a direct feedback loop. Clear examples of this can be recognized in CYPs metabolizing vitamin D (CYP24 and VDR) and retinoids (CYP26, CYP2C7 and RAR). PPAR α -, PXR- and CAR-activated *CYP4A*, *CYP3A* and *CYP2B* genes fall into this category: fatty acids and steroid hormones serve as ligands for PPAR α and PXR which in turn increase ligand elimination by CYP4A-mediated ω -hydroxylation [185] and CYP3A-catalysed 6 β -hydroxylation respectively [170]. Methoxychlor activates CAR and stimulates its own metabolism by CYP2B [145,301]. Candidates for this class might include CYP2A isoforms which are stereospecific androgen 7 α -

hydroxylases [302], present in testis and liver that are sites for androgen production and elimination respectively. Secondly, steroidogenic, vitamin D (CYP2D25) and cholesterol-metabolizing CYPs produce ligands for major classes of NRs, but the immediate CYP product is not a ligand for the suppressor. Instead, a more complex loop, either through the pituitary via action of trophic hormones (e.g. sex steroids and CYP17, CYP19, sex-specific hepatic CYPs) or through suppression by ultimate products (e.g. bile acids and CYP7A), is employed. Thirdly, some CYPs may ensure a steady elimination of a wide range of endobiotics or xenobiotics. This is made possible by prominent basal and liver-specific *CYP* gene expression that is controlled by HNF-4 or related orphan receptors. Certain CYPs in gene families *CYP2A*, *CYP2C*, *CYP2D* and *CYP3A* belong to this class. For these, no activating ligand or feedback loop are evident. However, they may be indirectly suppressed by CYP inducers or NR ligands (e.g. [102,103,110]).

Formation of NR ligands

In addition to the above feedback regulation, CYPs can often produce metabolites that act as ligands for unrelated NRs. Especially in the case of xenobiotics, this can result in production of potential disruption of cellular homeostasis. For examples, CYP1A2 and CYP2C19 enzymes form oestrogenic metabolites from methoxychlor [303], and a metabolite of PPAR α ligand can activate the PPAR γ [201]. In addition, inefficient removal of xenobiotics by CYPs may disrupt NR signalling (e.g. [93,98–100]). In the case of endobiotics, production of such 'unrelated' ligands may be less frequent, but formation of LXR α -activating sterols by CYP51 and CYP46 and retinoid formation by CYP1A may be such instances, and the androgen action in the brain is mediated by the CYP-dependent metabolism to oestrogen and ER α [122,127]. More details of this interwoven regulation and metabolism of *CYP* genes by endobiotics and xenobiotics are clearly needed.

The past decade has brought new evidence that enhances the role of CYP enzymes as active participants in the control of cellular homeostasis, instead of passive, low-specificity enzymes for general chemical elimination. CYP enzymes are involved in regulation of cellular levels of many endocrine and intracrine compounds that act via nuclear receptors. The regulatory triangle involving ligands, CYPs and nuclear receptors is completed by recent findings that ligand-activated nuclear receptors are responsible for the expression of major classes of CYP enzymes.

We apologize for the fact that, because of space constraints, full citation of all relevant articles has not been possible. We thank our colleagues at the NIEHS for collaboration and discussions, and Dr. Risto Juvonen and M. S. Maarit Korhonen for their comments on the manuscript before its submission. P. H. is a Senior Fellow of the Academy of Finland (award no. 66655).

REFERENCES

- Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W. et al. (1996) P450 superfamily: update on new sequences, gene mapping, accession numbers, and nomenclature. *Pharmacogenetics* **6**, 1–42
- Nelson, D. R. (1999) Cytochrome P450 and the individuality of species. *Arch. Biochem. Biophys.* **369**, 1–10
- Negishi, M., Uno, T., Darden, T. A., Sueyoshi, T. and Pedersen, L. P. (1996) Structural flexibility and functional versatility of mammalian P450 enzymes. *FASEB J.* **10**, 683–689
- Peterson, J. A. and Graham, S.E. (1998) A close family resemblance: the importance of structure in understanding cytochromes P450. *Structure* **6**, 1079–1085
- Guengerich, F. P. (1997) Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species. *Chem.–Biol. Interact.* **106**, 161–182

- 6 Rendic, S. and DiCarlo, F. J. (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. *Drug Metab. Rev.* **29**, 413–580
- 7 Waxman, D. J. and Azaroff, L. (1992) Phenobarbital induction of cytochrome P450 gene expression. *Biochem. J.* **281**, 577–592
- 8 Denison, M. S. and Whitlock, J. P. (1995) Xenobiotic-inducible transcription of cytochrome P450 genes. *J. Biol. Chem.* **270**, 18175–18178
- 9 Waxman, D. J. (1999) P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. *Arch. Biochem. Biophys.* **369**, 11–23
- 10 Meyer, U. A. and Zanger, U. M. (1997) Molecular mechanisms of genetic polymorphisms of drug metabolism. *Annu. Rev. Pharmacol. Toxicol.* **37**, 269–296
- 11 Taningher, M., Malacarne, D., Izzotti, A., Ugolini, D. and Parodi, S. (1999) Drug metabolism polymorphisms as modulators of cancer susceptibility. *Mutat. Res.* **436**, 227–261
- 12 Waxman, D. J. (1988) Interactions of hepatic cytochromes P450 with steroid hormones. *Biochem. Pharmacol.* **37**, 71–84
- 13 Rifkind, A. B., Lee, C., Chang, T. K. and Waxman, D. J. (1995) Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic epoxidation in human liver microsomes. *Arch. Biochem. Biophys.* **320**, 380–389
- 14 Duester, G. (1996) Involvement of alcohol dehydrogenase, short chain dehydrogenase/reductase, aldehyde dehydrogenase, and cytochrome P450 in the control of retinoid signaling by activation of retinoic acid synthesis. *Biochemistry* **35**, 12221–12227
- 15 Harder, D. R., Campbell, W. B. and Roman, R. J. (1995) Role of cytochrome P450 enzymes and metabolites of arachidonic acid in the control of vascular tone. *J. Vasc. Res.* **32**, 79–82
- 16 Waxman, D. J. and Chang, T. K. H. (1995) Hormonal regulation of liver cytochrome P450 enzymes. In *Cytochrome P450: Structure, Mechanism, and Biochemistry*, 2nd edn. (Ortiz de Montellano, P. R., ed.), pp. 391–417, Plenum Press, New York
- 17 Nebert, D. W. (1991) Proposed role of drug-metabolizing enzymes: regulation of steady state levels of the ligands that effect growth, homeostasis, differentiation, and neuroendocrine functions. *Mol. Endocrinol.* **5**, 1203–1214
- 18 Andreola, F., Fernandez-Salguero, P. M., Chiantore, M. V., Petkovich, M. P., Gonzalez, F. J. and De Luca, L. M. (1997) Aryl hydrocarbon receptor knockout mice (AhR^{-/-}) exhibit liver retinoid accumulation and reduced retinoic acid metabolism. *Cancer Res.* **57**, 2835–2838
- 19 Plasilova, M., Stoilov, I., Sarfarasi, M., Kadasi, L., Ferakova, E. and Ferak, V. (1999) Identification of a single ancestral CYP1B1 mutation in Slovak gypsies (Rom) affected with primary congenital glaucoma. *J. Med. Genet.* **36**, 290–294
- 20 Keeney, D. S. and Waterman, M. R. (1993) Regulation of steroid hydroxylase gene expression: importance to physiology and disease. *Pharmacol. Ther.* **58**, 301–317
- 21 Jones, G., Strugnell, S. A. and DeLuca, H. F. (1998) Current understanding of the molecular actions of vitamin D. *Physiol. Rev.* **78**, 1193–1231
- 22 White, P. C. (1994) Genetic diseases of steroid metabolism. *Vitam. Horm.* **49**, 131–195
- 23 Setchell, K. D. R., Schwarz, M., O'Connell, N. C., Lund, E. G., Davis, D. L., Lathe, R., Thompson, H. R., Tyson, R. W., Sokol, R. J. and Russell, D. W. (1998) Identification of a new inborn error in bile acid synthesis: mutation of the oxysterol 7 α -hydroxylase gene causes severe neonatal liver disease. *J. Clin. Invest.* **102**, 1690–1703
- 24 Mangelsdorf, D. J., Thummel, C., Beato, M., Herrlich, P., Schütz, G., Umesono, K., Blumberg, B., Kastner, P., Mark, M., Chambon, P. and Evans, R. M. (1995) The nuclear receptor superfamily: the second decade. *Cell* **83**, 835–839
- 25 Kastner, P., Mark, M. and Chambon, P. (1995) Nonsteroid nuclear receptors: what are genetic studies telling us about their role in real life? *Cell* **83**, 859–869
- 26 Enmark, E. and Gustafsson, J.-Å. (1996) Orphan nuclear receptors – the first eight years. *Mol. Endocrinol.* **10**, 1293–1307
- 27 Nuclear Receptors Nomenclature Committee (1999) A unified nomenclature system for the nuclear receptor superfamily. *Cell* **97**, 161–163
- 28 Forrest, D., Golarai, G., Connor, J. and Curran, T. (1996) Genetic analysis of thyroid hormone receptors in development and disease. *Recent Prog. Horm. Res.* **51**, 1–22
- 29 Minucci, S. and Pelicci, P. G. (1999) Retinoid receptors in health and disease: co-regulators and the chromatin connection. *Semin. Cell Dev. Biol.* **10**, 215–225
- 30 Yong, E. L., Tut, T. G., Ghadessy, F. J., Prins, G. and Ratnam, S. S. (1998) Partial androgen insensitivity and correlations with the predicted three dimensional structure of the androgen receptor ligand-binding domain. *Mol. Cell. Endocrinol.* **137**, 41–50
- 31 Mangelsdorf, D. J. and Evans, R. M. (1995) The RXR heterodimers and orphan receptors. *Cell* **83**, 841–850
- 32 Wilson, T. E., Mouw, A. R., Weaver, C. A., Milbrandt, J. and Parker, K. L. (1993) The orphan nuclear receptor NGFI-B regulates expression of the gene encoding steroid 21-hydroxylase. *Mol. Cell. Biol.* **13**, 861–868
- 33 Willy, P., Umesono, K., Ong, E. S., Evans, R. M., Heyman, R. A. and Mangelsdorf, D. J. (1995) LXR, a nuclear receptor that defines a distinct retinoid response pathway. *Genes Dev.* **9**, 1033–1045
- 34 Juge-Aubry, C., Pernin, A., Favez, T., Burger, A. G., Wahli, W., Meier, C. A. and Desvergne, B. (1997) DNA binding properties of peroxisome proliferator-activated receptor subtypes on various natural peroxisome proliferator response elements. *J. Biol. Chem.* **272**, 25252–25259
- 35 Rastinejad, F., Perlmann, T., Evans, R. M. and Sigler, P. B. (1995) Structural determinants of nuclear receptor assembly on DNA direct repeats. *Nature (London)* **375**, 203–211
- 36 Meinke, G. and Sigler, P. B. (1999) DNA-binding mechanism of the monomeric orphan nuclear receptor NGFI-B. *Nat. Struct. Biol.* **6**, 471–477
- 37 Hsu, M. H., Palmer, C. N., Song, W., Griffin, K. J. and Johnson, E. F. (1998) A carboxyl-terminal extension of the zinc finger domain contributes to the specificity and polarity of peroxisome proliferator-activated receptor DNA binding. *J. Biol. Chem.* **273**, 27988–27997
- 38 Zechel, C., Shen, X. Q., Chambon, P. and Gronemeyer, H. (1994) The dimerization interfaces formed between the DNA binding domains of RXR, RAR, and TR determine the binding specificity and polarity of the full-length receptors to direct repeats. *EMBO J.* **13**, 1414–1424
- 39 Perlmann, T., Umesono, K., Rangarajan, P. N., Forman, B. M. and Evans, R. M. (1996) Two distinct dimerization interfaces differentially modulate target gene specificity of nuclear hormone receptors. *Mol. Endocrinol.* **10**, 958–966
- 40 Tanenbaum, D. M., Wang, Y., Williams, S. P. and Sigler, P. B. (1998) Crystallographic comparison of the estrogen and progesterone receptor's ligand binding domains. *Proc. Natl. Acad. Sci. U.S.A.* **95**, 5998–6003
- 41 Moras, D. and Gronemeyer, H. (1998) The nuclear receptor ligand-binding domain: structure and function. *Curr. Opin. Cell Biol.* **10**, 384–391
- 42 Wagner, R. L., Apriletti, J. W., McGrath, M. E., West, B. L., Baxter, J. D. and Fletterick, R. J. (1995) A structural role for hormone in the thyroid hormone receptor. *Nature (London)* **378**, 690–697
- 43 Brzozowski, A. M., Pike, A. C. W., Dauter, Z., Hubbard, R. E., Bonn, T., Engström, O., Öhman, L., Greene, G. L., Gustafsson, J.-Å. and Carlquist, M. (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. *Nature (London)* **389**, 753–758
- 44 Nolte, R. T., Wisely, G. B., Westin, S., Cobb, J. E., Lambert, M. H., Kurokawa, R., Rosenfeld, M. G., Willson, T. M., Glass, C. K. and Milburn, M. V. (1998) Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor- γ . *Nature (London)* **395**, 137–143
- 45 Glass, C. K., Rose, D. W. and Rosenfeld, M. G. (1997) Nuclear receptor coactivators. *Curr. Opin. Cell Biol.* **9**, 222–232
- 46 Xu, L., Glass, C. K. and Rosenfeld, M. G. (1999) Coactivator and corepressor complexes in nuclear receptor function. *Curr. Opin. Genet. Dev.* **9**, 140–147
- 47 Darimont, B. D., Wagner, R. L., Apriletti, J. W., Stallcup, M. R., Kushner, P. J., Baxter, J. D., Fletterick, R. J. and Yamamoto, K. R. (1998) Structure and specificity of nuclear receptor-coactivator interactions. *Genes Dev.* **12**, 3343–3356
- 48 Grant, P. A. and Berger, S. L. (1999) Histone acetyltransferase complexes. *Semin. Cell Dev. Biol.* **10**, 169–177
- 49 Johnson, C. A. and Turner, B. M. (1999) Histone deacetylases: complex transducers of nuclear signals. *Semin. Cell Dev. Biol.* **10**, 179–188
- 50 Shao, D., Rangwala, S. M., Bailey, S. T., Krakow, S. L., Reginato, M. J. and Lazar, M. A. (1998) Interdomain communication regulating ligand binding by PPAR- γ . *Nature (London)* **396**, 377–380
- 51 Hammer, G. D., Krylova, I., Zhang, Y., Darimont, B. D., Simpson, K., Weigel, N. L. and Ingraham, H. A. (1999) Phosphorylation of the nuclear receptor SF-1 modulates cofactor recruitment: integration of the hormone signaling in reproduction and stress. *Mol. Cell* **3**, 521–526
- 52 Crofts, L. A., Hancock, M. S., Morrison, N. A. and Eisman, J. A. (1998) Multiple promoters direct the tissue-specific expression of novel N-terminal variant human vitamin D receptor gene transcripts. *Proc. Natl. Acad. Sci. U.S.A.* **95**, 10529–10534
- 53 Fasco, M. J. (1998) Estrogen receptor mRNA splice variants produced from the distal and proximal promoter transcripts. *Mol. Cell. Endocrinol.* **138**, 51–59
- 54 Guiochon-Mantel, A., Delabre, K., Lescop, P. and Milgrom, E. (1996) Intracellular traffic of steroid hormone receptors. *J. Steroid Biochem. Mol. Biol.* **56**, 1–6
- 55 Zhu, X.-G., Hanover, J. A., Hager, G. L. and Cheng, S. (1998) Hormone-induced translocation of thyroid hormone receptors in living cells using a green fluorescent protein chimera. *J. Biol. Chem.* **273**, 27058–27063
- 56 Weigel, N. L. (1996) Steroid hormone receptors and their regulation by phosphorylation. *Biochem. J.* **319**, 657–667
- 57 Shao, D. and Lazar, M. A. (1998) Modulating nuclear receptor function: may the phos be with you. *J. Clin. Invest.* **103**, 1617–1618
- 58 Kim, J. H., Stansbury, K. H., Walker, N. J., Trush, M. A., Strickland, P. T. and Sutter, T. R. (1998) Metabolism of benzo[a]pyrene and benzo[a]pyrene-7,8-diol by human cytochrome P450 1B1. *Carcinogenesis* **19**, 1847–1853
- 59 Martucci, C. P. and Fishman, J. (1993) P450 enzymes of estrogen metabolism. *Pharmacol. Ther.* **57**, 237–257

- 60 Hayes, C. L., Spink, D. C., Spink, B. C., Cao, J. Q., Walker, N. J. and Sutter, T. R. (1996) 17 β -Estradiol hydroxylation catalyzed by human cytochrome P450 1B1. *Proc. Natl. Acad. Sci. U.S.A.* **93**, 9776–9781
- 61 Hankinson, O. (1995) The aryl hydrocarbon receptor complex. *Annu. Rev. Pharmacol. Toxicol.* **35**, 307–340
- 62 Chen, Y. H. and Tukey, R. H. (1996) Protein kinase C modulates regulation of the *CYP1A1* gene by the aryl hydrocarbon receptor. *J. Biol. Chem.* **271**, 26261–26266
- 63 Carrier, F., Owens, R. A., Nebert, D. W. and Puga, A. (1992) Dioxin-dependent activation of murine *Cyp1a-1* gene transcription requires protein kinase C-dependent phosphorylation. *Mol. Cell. Biol.* **12**, 1856–1863
- 64 Mathis, J. M., Prough, R. A., Hines, R. N., Bresnick, E. and Simpson, E. R. (1986) Regulation of cytochrome P450c by glucocorticoids and polycyclic aromatic hydrocarbons in cultured fetal rat hepatocytes. *Arch. Biochem. Biophys.* **246**, 439–448
- 65 Sidhu, J. S. and Omiecinski, C. J. (1995) Modulation of xenobiotic-inducible cytochrome P450 gene expression by dexamethasone in primary rat hepatocytes. *Pharmacogenetics* **5**, 24–36
- 66 Celander, M., Weisbrod, R. and Stegeman, J. J. (1997) Glucocorticoid potentiation of cytochrome P4501A1 induction by 2,3,7,8-tetrachlorodibenzo-*p*-dioxin in porcine and human endothelial cells in culture. *Biochem. Biophys. Res. Commun.* **232**, 749–753
- 67 Sherratt, A. J., Banet, D. E., Linder, M. W. and Prough, R. A. (1989) Potentiation of 3-methylcholanthrene induction of cytochrome P4501A1 by dexamethasone *in vivo*. *J. Pharmacol. Exp. Ther.* **249**, 667–672
- 68 Mathis, J. M., Houser, W. H., Bresnick, E., Cidlowski, J. A., Hines, R. N., Prough, R. A. and Simpson, E. R. (1989) Glucocorticoid receptor regulation of the rat cytochrome P450c (*P4501A1*) gene: receptor binding within intron I. *Arch. Biochem. Biophys.* **269**, 93–105
- 69 Linder, M. W., Falkner, K. C., Srinivasan, G., Hines, R. N. and Prough, R. A. (1999) Role of canonical glucocorticoid responsive elements in modulating expression of genes regulated by the arylhydrocarbon receptor. *Drug Metab. Rev.* **31**, 247–271
- 70 Brake, P. B., Zhang, L. and Jefcoate, C. R. (1998) Aryl hydrocarbon receptor regulation of cytochrome P4501B1 in rat mammary fibroblasts: evidence for transcriptional repression by glucocorticoids. *Mol. Pharmacol.* **54**, 825–833
- 71 König, H., Ponta, H., Rahmsdorf, H. J. and Herrlich, P. (1992) Interference between pathway-specific transcription factors: glucocorticoids antagonize phorbol ester-induced AP-1 activity without altering AP-1 site occupation *in vivo*. *EMBO J.* **11**, 2241–2246
- 72 Thomsen, J. S., Wang, X., Hines, R. N. and Safe, S. (1994) Restoration of aryl hydrocarbon (Ah) responsiveness in MDA-MB-231 human breast cancer cells by transient expression of the estrogen receptor. *Carcinogenesis* **15**, 933–937
- 73 Spink, B. C., Fasco, M. J., Gierthy, J. F. and Spink, D. C. (1998) 12-*O*-tetradecanoylphorbol 13-acetate upregulates the Ah receptor and differentially alters CYP1B1 and CYP1A1 expression in MCF-7 breast cancer cells. *J. Cell. Biochem.* **70**, 289–296
- 74 Jana, N. R., Sarkar, S., Ishizuka, M., Yonemoto, J., Tohyama, C. and Sone, H. (1999) Role of estrogen receptor- α in differential expression of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin-inducible genes in the RL95-2 and KLE human endometrial cancer cell lines. *Arch. Biochem. Biophys.* **368**, 31–39
- 75 Angus, W. G., Larsen, M. C. and Jefcoate, C. R. (1999) Expression of CYP1A1 and CYP1B1 depends on cell-specific factors in human breast cancer cell lines: role of estrogen receptor status. *Carcinogenesis* **20**, 947–955
- 76 Ignar-Trowbridge, D. M., Nelson, K. G., Bidwell, M. C., Curtis, S. W., Washburn, T. F., McLachlan, J. A. and Korach, K. S. (1992) Coupling of dual signaling pathways: epidermal growth factor action involves the estrogen receptor. *Proc. Natl. Acad. Sci. U.S.A.* **89**, 4658–4662
- 77 Bunone, G., Briand, P.-A., Miksicek, R. J. and Picard, D. (1996) Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. *EMBO J.* **15**, 2174–2183
- 78 Korach, K. S., Couse, J. F., Curtis, S. W., Washburn, T. D., Lindzey, J., Kimbro, K. S., Eddy, E. M., Migliaccio, S., Snedeker, S. M., Lubahn, D. B. et al. (1996) Estrogen receptor gene disruption: molecular characterization and experimental and clinical phenotypes. *Recent Prog. Horm. Res.* **51**, 159–186
- 79 Kharat, I. and Saatcioglu, F. (1996) Antiestrogenic effects of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin are mediated by direct interference with the liganded estrogen receptor. Crosstalk between aryl hydrocarbon- and estrogen-mediated signaling. *J. Biol. Chem.* **271**, 10533–10537
- 80 Hoivik, D., Willett, K., Wilson, C. and Safe, S. (1997) Estrogen does not inhibit 2,3,7,8-tetrachlorodibenzo-*p*-dioxin-mediated effects in MCF-7 and Hepa 1c1c7 cells. *J. Biol. Chem.* **272**, 30270–30274
- 81 Ricci, M. S., Toscano, D. G., Mattingly, C. J. and Toscano, Jr., W. A. (1999) Estrogen receptor reduces CYP1A1 induction in cultured human endometrial cells. *J. Biol. Chem.* **274**, 3430–3438
- 82 Kumar, M. B., Tarpey, R. W. and Perdew, G. H. (1999) Differential recruitment of coactivator RIP140 by Ah and estrogen receptors. Absence of a role for LXXLL motifs. *J. Biol. Chem.* **274**, 22155–22164
- 83 Nguyen, T. A., Hoivik, D., Lee, J. E. and Safe, S. (1999) Interactions of nuclear receptor coactivator/corepressor proteins with the aryl hydrocarbon receptor complex. *Arch. Biochem. Biophys.* **367**, 250–257
- 84 Mäkelä, S., Savolainen, H., Aavik, E., Myllärniemi, M., Strauss, L., Taskinen, E., Gustafsson, J.-Å. and Häyry, P. (1999) Differentiation between vasculoprotective and uterotrophic effects of ligands with different binding affinities to estrogen receptors α and β . *Proc. Natl. Acad. Sci. U.S.A.* **96**, 7077–7082
- 85 Vanacker, J. M., Pettersson, K., Gustafsson, J.-Å. and Laudet, V. (1999) Transcriptional targets shared by estrogen receptor-related receptors (ERRs) and estrogen receptor (ER) α , but not by ER β . *EMBO J.* **18**, 4270–4279
- 86 Vanacker, J. M., Bonnelye, E., Chopin-Delannoy, S., Delmarre, C., Cavaillès, V. and Laudet, V. (1999) Transcriptional activities of the orphan nuclear receptor ERR α (estrogen receptor-related receptor α). *Mol. Endocrinol.* **13**, 764–773
- 87 Li, X.-Y., Åstrom, A., Duell, E. A., Qin, L., Griffiths, C. E. and Voorhees, J. J. (1995) Retinoic acid antagonizes basal as well as coal tar- and glucocorticoid-induced cytochrome P450 1A1 expression in human skin. *Carcinogenesis* **16**, 519–525
- 88 Wanner, R., Brommer, S., Czarnetzki, B. M. and Rosenbach, T. (1995) The differentiation-related upregulation of aryl hydrocarbon receptor transcript levels is suppressed by retinoic acid. *Biochem. Biophys. Res. Commun.* **209**, 706–711
- 89 Vecchini, F., Mace, K., Magdalou, J., Mahe, Y., Bernard, B. A. and Shroot, B. (1995) Constitutive and inducible expression of drug metabolizing enzymes in cultured human keratinocytes. *Br. J. Dermatol.* **132**, 14–21
- 90 Vecchini F., Lenoir-Viale, M. C., Cathelineau, C., Magdalou, J., Bernard, B. A. and Shroot, B. (1994) Presence of a retinoid responsive element in the promoter region of the human cytochrome *P4501A1* gene. *Biochem. Biophys. Res. Commun.* **201**, 1205–1212
- 91 Jurima-Romet, M., Neigh, S. and Casley, W. L. (1997) Induction of cytochrome P4503A by retinoids in rat hepatocyte culture. *Hum. Exp. Toxicol.* **16**, 198–203
- 92 Howell, S. R., Shirley, M. A. and Ulm, E. H. (1998) Effects of retinoid treatment of rats on hepatic microsomal metabolism and cytochromes P450. Correlation between retinoic acid receptor/retinoid X receptor selectivity and effects on metabolic enzymes. *Drug Metab. Dispos.* **26**, 234–239
- 93 Safe, S., Wang, F., Porter, W., Duan, R. and McDougal, A. (1998) Ah receptor agonists as endocrine disruptors: antiestrogenic activity and mechanisms. *Toxicol. Lett.* **102–103**, 343–347
- 94 Krishnan, V., Porter, W., Santostefano, M., Wang, X. and Safe, S. (1995) Molecular mechanism of inhibition of estrogen-induced cathepsin D gene expression by 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) in MCF-7 cells. *Mol. Cell. Biol.* **15**, 6710–6719
- 95 Wang, X., Porter, W., Krishnan, V., Narasimhan, T. R. and Safe, S. (1993) Mechanism of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD)-mediated decrease of the nuclear estrogen receptor in MCF-7 human breast cancer cells. *Mol. Cell. Endocrinol.* **96**, 159–166
- 96 Gierthy, J. F., Spink, B. C., Figge, H. L., Pentecost, B. T. and Spink, D. C. (1996) Effects of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin, 12-*O*-tetradecanoylphorbol 13-acetate and 17 α -estradiol on estrogen receptor regulation in MCF-7 human breast cancer cells. *J. Cell. Biochem.* **60**, 173–184
- 97 Sunahara, G. I., Guenat, C. and Griew, F. (1989) Characterization of 3-methylcholanthrene effects on the rat glucocorticoid receptor *in vivo*. *Cancer Res.* **49**, 3535–3541
- 98 Lin, F. J., Stohs, S. J., Birnbaum, L. S., Clark, G., Lucier, G. W. and Goldstein, J. A. (1991) The effects of 2,3,7,8-tetrachlorodibenzo-*p*-dioxin (TCDD) on the hepatic estrogen and glucocorticoid receptors in congenic strains of Ah responsive and Ah nonresponsive C57BL/6J mice. *Toxicol. Appl. Pharmacol.* **108**, 129–139
- 99 Lorick, K. L., Toscano, D. L. and Toscano, Jr., W. A. (1998) 2,3,7,8-tetrachlorodibenzo-*p*-dioxin alters retinoic acid receptor function in human keratinocytes. *Biochem. Biophys. Res. Commun.* **243**, 749–752
- 100 Alexander, D. L., Ganem, L. G., Fernandez-Salguero, P., Gonzalez, F. and Jefcoate, C. R. (1998) Aryl hydrocarbon receptor is an inhibitory regulator of lipid synthesis and of commitment to adipogenesis. *J. Cell Sci.* **111**, 3311–3322
- 101 Sewall, C. H., Flagler, N., Vanden Heuvel, J. P., Clark, G. C., Tritscher, A. M., Maronpot, R. M. and Lucier, G. W. (1995) Alterations in thyroid function in female Sprague-Dawley rats following chronic treatment with 2,3,7,8-tetrachlorodibenzo-*p*-dioxin. *Toxicol. Appl. Pharmacol.* **132**, 237–244
- 102 Emi, Y. and Omura, T. (1988) Synthesis of sex-specific forms of cytochrome P450 in rat liver is transiently suppressed by hepatic monooxygenase inducers. *J. Biochem. (Tokyo)* **104**, 40–43
- 103 Yeowell, H. N., Waxman, D. J., Wadhwa, A. and Goldstein, J. A. (1987) Suppression of the constitutive, male-specific rat hepatic cytochrome P450 2c and its mRNA by 3,4,5,3',4',5'-hexachlorobiphenyl and 3-methylcholanthrene. *Mol. Pharmacol.* **32**, 340–347

- 104 Fernandez-Salguero, P. M., Pineau, T., Hilbert, D. M., McPhail, T., Lee, S. S., Kimura, S., Nebert, D. W., Rudikoff, S., Ward, J. M. and Gonzalez, F. J. (1995) Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. *Science* **268**, 722–726
- 105 Roberts, E. S., Vaz, A. D. and Coon, M. J. (1992) Role of isozymes of rabbit microsomal cytochrome P450 in the metabolism of retinoic acid, retinol, and retinal. *Mol. Pharmacol.* **41**, 427–433
- 106 Raner, G. M., Vaz, A. D. and Coon, M. J. (1996) Metabolism of all-*trans*, 9-*cis*, and 13-*cis* isomers of retinal by purified isozymes of microsomal cytochrome P450 and mechanism-based inhibition of retinoid oxidation by citral. *Mol. Pharmacol.* **49**, 515–522
- 107 Liang, H. C., Li, H., McKinnon, R. A., Duffy, J. J., Potter, S. S., Puga, A. and Nebert, D. W. (1996) *Cyp1a2*(–/–) null mutant mice develop normally but show deficient drug metabolism. *Proc. Natl. Acad. Sci. U.S.A.* **93**, 1671–1676
- 108 Gonzalez, F. J. and Lee, Y.-H. (1996) Constitutive expression of hepatic cytochrome P450 genes. *FASEB J.* **10**, 1112–1117
- 109 Park, Y. and Kemper, B. (1996) The *CYP2B1* proximal promoter contains a functional C/EBP regulatory element. *DNA Cell Biol.* **15**, 693–701
- 110 Corton, J. C., Fan, L. Q., Brown, S., Anderson, S. P., Bocos, C., Cattley, R. C. and Gustafsson, J.-Å. (1998) Down-regulation of cytochrome P450 2C family members and positive acute-phase response gene expression by peroxisome proliferator chemicals. *Mol. Pharmacol.* **54**, 463–473
- 111 Venepally, P., Chen, D. and Kemper, B. (1992) Transcriptional regulatory elements for basal expression of cytochrome *P450IIC* genes. *J. Biol. Chem.* **267**, 17333–17338
- 112 Fraser, J. D., Martinez, V., Straney, R. and Briggs, M. R. (1998) DNA binding and transcription activation specificity of hepatocyte nuclear factor 4. *Nucleic Acids Res.* **26**, 2702–2706
- 113 Chen, D., Lepar, G. and Kemper, B. (1994) A transcriptional regulatory element common to a large family of hepatic cytochrome *P450* genes is a functional binding site of the orphan receptor HNF-4. *J. Biol. Chem.* **269**, 5420–5427
- 114 Chen, D., Park, Y. and Kemper, B. (1994) Differential protein binding and transcriptional activities of HNF-4 elements in three closely related *CYP2C* genes. *DNA Cell Biol.* **13**, 771–779
- 115 Ibeanu, G. C. and Goldstein, J. A. (1995) Transcriptional regulation of human *CYP2C* genes: functional comparison of *CYP2C9* and *CYP2C18* promoter regions. *Biochemistry* **34**, 8028–8036
- 116 Yokomori, N., Nishio, K., Aida, K. and Negishi, M. (1997) Transcriptional regulation by HNF-4 of the steroid 15 α -hydroxylase P450 (*Cyp2a-4*) gene in mouse liver. *J. Steroid Biochem. Mol. Biol.* **62**, 307–314
- 117 Huss, J. M. and Kasper, C. B. (1998) Nuclear receptor involvement in the regulation of rat P450 3A23 expression. *J. Biol. Chem.* **273**, 16155–16162
- 118 Ogino, M., Nagata, K., Miyata, M. and Yamazoe, Y. (1999) Hepatocyte nuclear factor 4-mediated activation of rat *CYP3A1* gene and its modes of modulation by apolipoprotein A1 regulatory protein I and *v-ErbA*-related protein 3. *Arch. Biochem. Biophys.* **362**, 32–37
- 119 Yoshioka, H., Lang, M., Wong, G. and Negishi, M. (1990) A specific *cis*-acting element regulates *in vitro* transcription of sex-dependent mouse steroid 16 α -hydroxylase (C-P45016 α) gene. *J. Biol. Chem.* **265**, 14612–14617
- 120 Legraverend, C., Eguchi, H., Ström, A., Lahuna, O., Mode, A., Tollet, P., Westin, S. and Gustafsson, J.-Å. (1994) Transactivation of the rat *CYP2C13* gene promoter involves HNF-1, HNF-3, and members of the orphan receptor subfamily. *Biochemistry* **33**, 9889–9897
- 121 Ström, A., Westin, S., Eguchi, H., Gustafsson, J.-Å. and Mode, A. (1995) Characterization of orphan nuclear receptor binding elements in sex-differentiated members of the *CYP2C* gene family expressed in rat liver. *J. Biol. Chem.* **270**, 11276–11281
- 122 Sueyoshi, T., Yokomori, N., Korach, K. S. and Negishi, M. (1999) Developmental action of estrogen receptor- α feminizes the growth hormone-Stat5b pathway and expression of *Cyp2a4* and *Cyp2d9* genes in mouse liver. *Mol. Pharmacol.* **56**, 473–477
- 123 Sundseth, S. S., Alberta, J. A. and Waxman, D. J. (1992) Sex-specific, growth hormone-regulated transcription of the cytochrome P450 2C11 and 2C12 genes. *J. Biol. Chem.* **267**, 3907–3914
- 124 Legraverend, C., Mode, A., Westin, S., Ström, A., Eguchi, H., Zaphiropoulos, P. G. and Gustafsson, J.-Å. (1992) Transcriptional regulation of rat P-450 2C gene subfamily members by the sexually dimorphic pattern of growth hormone secretion. *Mol. Endocrinol.* **6**, 259–266
- 125 Noshiro, M. and Negishi, M. (1986) Pretranslational regulation of sex-dependent testosterone hydroxylases by growth hormone in mouse liver. *J. Biol. Chem.* **261**, 15923–15927
- 126 Udy, G. B., Towers, R. P., Snell, R. G., Wilkins, R. J., Park, S.-H., Ram, P. A., Waxman, D. J. and Davey, H. W. (1997) Requirement of STAT5b for sexual dimorphism of body growth rates and liver gene expression. *Proc. Natl. Acad. Sci. U.S.A.* **94**, 7239–7344
- 127 Roselli, C. E. and Klosterman, S. A. (1998) Sexual differentiation of aromatase activity in the rat brain: effects of perinatal steroid exposure. *Endocrinology* (Baltimore) **139**, 3193–3201
- 128 Fisher, C. R., Graves, K. H., Parlow, A. F. and Simpson, E. R. (1998) Characterization of mice deficient in aromatase (ArKO) because of targeted disruption of the *cyp19* gene. *Proc. Natl. Acad. Sci. U.S.A.* **95**, 6965–6970
- 129 Yang, C. S. and Lu, A. Y. H. (1988) The diversity of substrates for cytochrome P450. In *Mammalian Cytochromes P450*, vol. 2 (Guengerich, F. P., ed.), pp. 1–18, CRC Press, Boca Raton
- 130 Honkakoski, P. and Lang, M. A. (1989) The mouse liver phenobarbital-inducible P450 system. *Arch. Biochem. Biophys.* **273**, 42–57
- 131 Furster, C. and Wikvall, K. (1999) Identification of CYP3A4 as the major enzyme responsible for 25-hydroxylation of 5 β -cholestane-3 α ,7 α ,12 α -triol in human liver microsomes. *Biochim. Biophys. Acta* **1437**, 46–52
- 132 Omiecinski, C. J. (1986) Tissue-specific expression of rat mRNAs homologous to cytochromes P450b and P450e. *Nucleic Acids Res.* **14**, 1525–1539
- 133 Honkakoski, P., Kojo, A. and Lang, M. A. (1992) Regulation of mouse liver P450 2B subfamily by sex hormones and phenobarbital. *Biochem. J.* **285**, 979–983
- 134 Frueh, F. W., Zanger, U. M. and Meyer, U. A. (1997) Extent and character of pheno-barbital-induced changes in gene expression in the liver. *Mol. Pharmacol.* **51**, 363–369
- 135 Sidhu, J. S. and Omiecinski, C. J. (1998) Protein synthesis inhibitors exhibit a nonspecific effect on phenobarbital-inducible cytochrome P450 gene expression in primary rat hepatocytes. *J. Biol. Chem.* **273**, 4769–4775
- 136 Honkakoski, P. and Negishi, M. (1998) Protein serine/threonine phosphatase inhibitors suppress phenobarbital-induced *Cyp2b10* gene transcription in mouse primary hepatocytes. *Biochem. J.* **330**, 889–895
- 137 Sidhu, J. S. and Omiecinski, C. J. (1997) An okadaic acid-sensitive pathway involved in the phenobarbital-mediated induction of *CYP2B* gene expression in primary rat hepatocyte cultures. *J. Pharmacol. Exp. Ther.* **282**, 1122–1129
- 138 Honkakoski, P. and Negishi, M. (1998) Regulatory DNA elements of phenobarbital-responsive cytochrome P450 *CYP2B* genes. *J. Biochem. Mol. Toxicol.* **12**, 3–9
- 139 Ramsden, R., Sommer, K. M. and Omiecinski, C. J. (1993) Phenobarbital induction and tissue-specific expression of the rat *CYP2B2* gene in transgenic mice. *J. Biol. Chem.* **268**, 21722–21726
- 140 Hashimoto, T., Matsumoto, T., Nishizawa, M., Kawabata, S., Morohashi, K., Handa, S. and Omura, T. (1988) A mutant rat strain deficient in induction of a phenobarbital-inducible form of cytochrome P450 in liver microsomes. *J. Biochem. (Tokyo)* **103**, 487–492
- 141 Kende, A. S., Ebetino, F. H., Drendel, W. B., Sundaralingam, M., Glover, E. and Poland, A. (1985) Structure-activity relationship of bispridylloxybenzene for induction of mouse hepatic aminopyrine N-demethylase activity. *Mol. Pharmacol.* **28**, 445–453
- 142 Trottier, E., Belzil, A., Stoltz, C. and Anderson, A. (1995) Localization of a phenobarbital-responsive element (PBRE) in the 5'-flanking region of the rat *CYP2B2* gene. *Gene* **158**, 263–268
- 143 Park, Y., Li, H. and Kemper, B. (1996) Phenobarbital induction mediated by a distal *CYP2B2* sequence in rat liver transiently transfected *in situ*. *J. Biol. Chem.* **271**, 23725–23728
- 144 Honkakoski, P. and Negishi, M. (1997) Characterization of a phenobarbital-responsive enhancer module in mouse P450 *Cyp2b10* gene. *J. Biol. Chem.* **272**, 14943–14949
- 145 Sueyoshi, T., Kawamoto, T., Zelko, I., Honkakoski, P. and Negishi, M. (1999) The repressed nuclear receptor CAR responds to phenobarbital in activating the human *CYP2B6* gene. *J. Biol. Chem.* **274**, 6043–6046
- 146 Kim, J. and Kemper, B. (1997) Phenobarbital alters protein binding to the *CYP2B1/2* phenobarbital-responsive unit in native chromatin. *J. Biol. Chem.* **272**, 29423–29435
- 147 Honkakoski, P., Zelko, I., Sueyoshi, T. and Negishi, M. (1998) The orphan nuclear receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the *CYP2B* gene. *Mol. Cell Biol.* **18**, 5652–5658
- 148 Honkakoski, P., Moore, R., Washburn, K. and Negishi, M. (1998) Activation by diverse xenochemicals of the 51-base pair phenobarbital-responsive enhancer module in the *CYP2B10* gene. *Mol. Pharmacol.* **53**, 597–601
- 149 Ramsden, R., Beck, N. B., Sommer, K. M. and Omiecinski, C. J. (1999) Phenobarbital responsiveness conferred by the 5'-flanking region of the rat *CYP2B2* gene in transgenic mice. *Gene* **228**, 169–179
- 150 Baes, M., Gulick, T., Choi, H. S., Martinoli, M. G., Simha, D. and Moore, D. D. (1994) A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements. *Mol. Cell Biol.* **14**, 1544–1551
- 151 Lehmann, J. M., McKee, D. D., Watson, M. A., Willson, T. M., Moore, T. and Kliewer, S. A. (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate *CYP3A4* gene expression and cause drug interactions. *J. Clin. Invest.* **102**, 1016–1023

- 152 Choi, H. S., Chung, M., Tzamelis, I., Simha, D., Lee, Y. K., Seol, W. and Moore, D. D. (1997) Differential transactivation by two isoforms of the orphan nuclear hormone receptor CAR. *J. Biol. Chem.* **272**, 23565–23571
- 153 Honkakoski, P., Moore, R., Gynther, J. and Negishi, M. (1996) Characterization of phenobarbital-inducible mouse *Cyp2b10* gene transcription in primary hepatocytes. *J. Biol. Chem.* **271**, 9746–9753
- 154 Forman, B. M., Tzamelis, I., Choi, H. S., Chen, J., Simha, D., Seol, W., Evans, R. M. and Moore, D. D. (1998) Androstane metabolites bind to and deactivate the nuclear receptor CAR β . *Nature (London)* **395**, 612–615
- 155 Gower, D. B. and Ruparelia, B. A. (1993) Olfaction in humans with special reference to odorous 16-androstenes: their occurrence, perception and possible social, psychological and sexual impact. *J. Endocrinol.* **137**, 167–187
- 156 Kliewer, S. A., Lehmann, J. and Willson, T. M. (1999) Orphan nuclear receptors: shifting endocrinology into reverse. *Science* **284**, 757–760
- 157 Kocarek, T. A., Kraniak, J. M. and Reddy, A. B. (1998) Regulation of rat hepatic cytochrome P450 expression by sterol biosynthesis inhibition: inhibitors of squalene synthase are potent inducers of CYP2B expression in primary cultured rat hepatocytes and rat liver. *Mol. Pharmacol.* **54**, 474–484
- 158 Kawamoto, T., Sueyoshi, T., Zelko, I., Moore, R., Washburn, K. and Negishi, M. (1999) Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the *CYP2B* gene. *Mol. Cell. Biol.* **19**, 6318–6322
- 159 DeFranco, D. B., Qi, M., Borrer, K. C., Garabedian, M. J. and Brautigan, D. L. (1991) Protein phosphatase types 1 and/or 2A regulate nucleocytoplasmic shuttling of glucocorticoid receptors. *Mol. Endocrinol.* **5**, 1215–1228
- 160 Chang, T. K., Teixeira, J., Gil, G. and Waxman, D. J. (1993) The lithocholic acid 6 β -hydroxylase cytochrome P-450, CYP 3A10, is an active catalyst of steroid hormone 6 β -hydroxylation. *Biochem. J.* **291**, 429–433
- 161 Thummel, K. E. and Wilkinson, G. R. (1998) *In vitro* and *in vivo* drug interactions involving human CYP3A. *Annu. Rev. Pharmacol. Toxicol.* **38**, 389–430
- 162 Schuetz, J. D., Beach, D. L. and Guzelian, P. S. (1994) Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. *Pharmacogenetics* **4**, 11–20
- 163 Barwick, J. L., Quattrochi, L. C., Mills, A. S., Potenza, C., Tukey, R. H. and Guzelian, P. S. (1996) *Trans*-species gene transfer for analysis of glucocorticoid-inducible transcriptional activation of transiently expressed human *CYP3A4* and rabbit *CYP3A6* in primary cultures of adult rat and rabbit hepatocytes. *Mol. Pharmacol.* **50**, 10–16
- 164 Schuetz, E. G., Brimer, C. and Schuetz, J. D. (1998) Environmental xenobiotics and the anti-hormones cyproterone acetate and spironolactone use the nuclear hormone pregnenolone X receptor to activate the *CYP3A23* hormone response element. *Mol. Pharmacol.* **54**, 1113–1117
- 165 Quattrochi, L. C., Mills, A. S., Barwick, J. L., Yockey, C. B. and Guzelian, P. S. (1995) A novel *cis*-acting element in a liver cytochrome P450 *3A* gene confers synergistic induction by glucocorticoids plus antiglucocorticoids. *J. Biol. Chem.* **270**, 28917–28923
- 166 Huss, J. M., Wang, S. I., Astrom, A., McQuiddy, P. and Kasper, C. B. (1996) Dexamethasone responsiveness of a major glucocorticoid-inducible *CYP3A* gene is mediated by elements unrelated to a glucocorticoid receptor binding motif. *Proc. Natl. Acad. Sci. U.S.A.* **93**, 4666–4670
- 167 Pascussi, J.-M., Jounaidi, Y., Drocourt, L., Domergue, J., Balabaud, C., Maurel, P. and Vilarem, M.-J. (1999) Evidence for the presence of a functional pregnane X receptor response element in the *CYP3A7* gene promoter. *Biochem. Biophys. Res. Commun.* **260**, 377–381
- 168 Goodwin, B., Hodgson, E. and Liddle, C. (1999) The orphan human pregnane X receptor mediates the transcriptional activation of *CYP3A4* by rifampicin through a distal enhancer module. *Mol. Pharmacol.* **56**, 1329–1339
- 169 Blumberg, B., Sabbagh, W., Juguilon, H., Bolado, J., van Meter, C. M., Ong, E. S. and Evans, R. M. (1998) SXR, a novel steroid and xenobiotic-sensing nuclear receptor. *Genes Dev.* **12**, 3195–3205
- 170 Kliewer, S. A., Moore, J. T., Wade, L., Staudinger, J. L., Watson, M. A., Jones, S. A., McKee, D. D., Oliver, B. B., Willson, T. M., Zetterstrom, R. H., Perlmann, T. and Lehmann, J. M. (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. *Cell* **92**, 73–82
- 171 Bertilsson, G., Heidrich, J., Svensson, K., Asman, M., Jendeberg, L., Sydow-Bäckman, M., Ohlsson, R., Postlind, H., Blomquist, P. and Berkenstam, A. (1998) Identification of a human nuclear receptor defines a new signaling pathway for *CYP3A* induction. *Proc. Natl. Acad. Sci. U.S.A.* **95**, 12208–12213
- 172 Janowski, B. A., Grogan, M. J., Jones, S. A., Wisely, G. B., Kliewer, S. A., Corey, E. J. and Mangelsdorf, D. J. (1999) Structural requirements of ligands for the oxysterol liver X receptors LXR α and LXR β . *Proc. Natl. Acad. Sci. U.S.A.* **96**, 266–271
- 173 Traber, P. G., Wang, W., McDonnell, M. and Gumucio, J. J. (1990) *P450IIB* gene expression in rat small intestine: cloning of intestinal *CYP1B1* mRNA using the polymerase chain reaction and transcriptional regulation of induction. *Mol. Pharmacol.* **37**, 810–819
- 174 Meehan, R. R., Forrester, L. M., Stevenson, K., Hastie, N. D., Buchmann, A., Kunz, H. W. and Wolf, C. R. (1988) Regulation of phenobarbital-inducible cytochrome P450s in rat and mouse liver following dexamethasone administration and hypophysectomy. *Biochem. J.* **254**, 789–797
- 175 Kocarek, T. A., Schuetz, E. G. and Guzelian, P. S. (1990) Differentiated induction of cytochrome P450b/e and P450p mRNAs by dose of phenobarbital in primary cultures of rat hepatocytes. *Mol. Pharmacol.* **38**, 440–444
- 176 Jaiswal, A. K., Haaparanta, T., Luc, P.-V., Schembri, J. and Adesnik, M. (1990) Glucocorticoid regulation of a phenobarbital-inducible P450 gene: the presence of a functional glucocorticoid response element in the 5'-flanking region of the *CYP2B2* gene. *Nucleic Acids Res.* **18**, 4237–4242
- 177 Schuetz, J. D., Schuetz, E. G., Thottassery, J. V., Guzelian, P. S., Strom, S. and Sun, D. (1996) Identification of a novel dexamethasone responsive enhancer in the human *CYP3A5* gene and its activation in human and rat liver cells. *Mol. Pharmacol.* **49**, 63–72
- 178 Pereira, T. M., Carlstedt-Duke, J., Lechner, M. C. and Gustafson, J.-Å. (1998) Identification of a functional glucocorticoid response element in the *CYP3A1/IGC2* gene. *DNA Cell Biol.* **17**, 39–49
- 179 Burger, H.-J., Schuetz, J. D., Schuetz, E. G. and Guzelian, P. S. (1992) Paradoxical transcriptional activation of rat liver cytochrome P450 3A1 by dexamethasone and the antiglucocorticoid pregnenolone 16 α -carbonitrile: analysis by transient transfection into primary monolayer cultures of adult rat hepatocytes. *Proc. Natl. Acad. Sci. U.S.A.* **89**, 2145–2149
- 180 Zhang, H., LeCluyse, E., Liu, L., Hu, M., Matoney, L., Zhu, W. and Yan, B. (1999) Rat pregnane X receptor: molecular cloning, tissue distribution, and xenobiotic regulation. *Arch. Biochem. Biophys.* **368**, 14–22
- 181 Liddle, C., Goodwin, B. J., George, J., Tapner, M. and Farrell, G. C. (1998) Separate and interactive regulation of cytochrome P450 3A4 by triiodothyronine, dexamethasone, and growth hormone in cultured hepatocytes. *J. Clin. Endocrinol. Metab.* **83**, 2411–2416
- 182 Ganem, L. G., Trottier, E., Anderson, A. and Jefcoate, C. R. (1999) Phenobarbital induction of CYP2B1/2 in primary hepatocytes: endocrine regulation and evidence for a single pathway for multiple inducers. *Toxicol. Appl. Pharmacol.* **155**, 32–42
- 183 Seol, W., Choi, H. S. and Moore, D. D. (1996) An orphan nuclear hormone receptor that lacks a DNA binding domain and heterodimerizes with other receptors. *Science* **272**, 1336–1339
- 184 Johansson, L., Thomsen, J. S., Damdimopoulos, A. E., Stryou, G., Gustafsson, J.-Å. and Treuter, E. (1999) The orphan nuclear receptor SHP inhibits agonist-dependent transcriptional activity of estrogen receptors ER α and ER β . *J. Biol. Chem.* **274**, 345–353
- 185 Roman, L. J., Palmer, C. N. A., Clark, J. E., Muerhoff, A. S., Griffin, K. J., Johnson, E. F. and Masters, B. S. S. (1993) Expression of rabbit cytochromes P450A4 which catalyze the ω -hydroxylation of arachidonic acid, fatty acids, and prostaglandins. *Arch. Biochem. Biophys.* **307**, 57–65
- 186 Sharma, R., Lake, B. G. and Gibson, G. G. (1988) Co-induction of microsomal cytochrome P-452 and the peroxisomal fatty acid beta-oxidation pathway in the rat by clofibrate and di-(2-ethylhexyl)phthalate. Dose-response studies. *Biochem. Pharmacol.* **37**, 1203–1206
- 187 Issemann, I. and Green, S. (1990) Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. *Nature (London)* **347**, 645–650
- 188 Gonzalez, F. J., Peters, J. M. and Cattley, R. C. (1998) Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor α . *J. Natl. Cancer Inst.* **90**, 1702–1709
- 189 Varneq, J. and Latruffe, N. (1999) Medical significance of peroxisome proliferator-activated receptors. *Lancet* **354**, 141–148
- 190 Johnson, E. F., Palmer, C. N. A., Griffin, K. J. and Hsu, M. H. (1996) Role of the peroxisome proliferator-activated receptor in cytochrome *P450 4A* gene regulation. *FASEB J.* **10**, 1241–1248
- 191 Aldridge, T. C., Tugwood, J. D. and Green, S. (1995) Identification and characterization of DNA elements implicated in the regulation of *CYP4A1* transcription. *Biochem. J.* **306**, 473–479
- 192 Palmer, C. N. A., Hsu, M. H., Griffin, H. J. and Johnson, E. F. (1995) Novel sequence determinants in peroxisome proliferator signaling. *J. Biol. Chem.* **270**, 16114–16121
- 193 Nakshatri, H. and Bhat-Nakshatri, P. (1998) Multiple parameters determine the specificity of transcriptional response by nuclear receptors HNF-4, ARP-1, PPAR, RAR and RXR through common response elements. *Nucleic Acids Res.* **26**, 2491–2499
- 194 Castelein, H., Declercq, P. E. and Baes, M. (1997) DNA binding preferences of PPAR α /RXR α heterodimers. *Biochem. Biophys. Res. Commun.* **233**, 91–95
- 195 Göttlicher, M., Widmark, E., Li, Q. and Gustafsson, J.-Å. (1992) Fatty acids activate a chimera of the clofibrate acid-activated receptor and the glucocorticoid receptor. *Proc. Natl. Acad. Sci. U.S.A.* **89**, 4653–4657

- 196 Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J. and Wahli, W. (1996) The PPAR α -leukotriene B₄ pathway to inflammation control. *Nature* (London) **384**, 39–43
- 197 Yu, K., Bayona, W., Kallen, C. B., Harding, H. P., Ravera, C. P., McMahon, G., Brown, M. and Lazar, M. A. (1995) Differential activation of peroxisome proliferator-activated receptors by eicosanoids. *J. Biol. Chem.* **270**, 23975–23983
- 198 Forman, B. M., Chen, J. M. and Evans, R. M. (1997) Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ . *Proc. Natl. Acad. Sci. U.S.A.* **94**, 4312–4317
- 199 Lehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M. and Kliewer, S. A. (1997) Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal anti-inflammatory drugs. *J. Biol. Chem.* **272**, 81–94
- 200 Keller, H., Devchand, P. R., Perroud, M. and Wahli, W. (1997) PPAR α structure-function relationships derived from species-specific differences in responsiveness to hypolipidemic agents. *Biol. Chem.* **378**, 651–655
- 201 Maloney, E. K. and Waxman, D. J. (1999) *Trans*-activation of PPAR α and PPAR γ by structurally diverse environmental chemicals. *Toxicol. Appl. Pharmacol.* **161**, 209–218
- 202 Yan, Z. H., Karam, W. G., Staudinger, J. L., Medvedev, A., Ghanayem, B. I. and Jetten, A. M. (1998) Regulation of peroxisome proliferator-activated receptor α -induced transactivation by the nuclear orphan receptor TAK1/TR4. *J. Biol. Chem.* **273**, 10948–10957
- 203 Miyata, K. S., McCaw, S. E., Patel, H. V., Rachubinski, R. A. and Capone, J. P. (1996) The orphan nuclear hormone receptor LXR α interacts and inhibits peroxisome proliferator signaling. *J. Biol. Chem.* **271**, 9189–9192
- 204 Chu, R., Madison, L. D., Lin, Y., Kopp, P., Rao, M. S., Jameson, J. L. and Reddy, J. K. (1995) Thyroid hormone (T₃) inhibits ciprofibrate-induced transcription of genes encoding beta-oxidation enzymes: cross talk between peroxisome proliferator and T₃ signaling pathways. *Proc. Natl. Acad. Sci. U.S.A.* **92**, 11593–11597
- 205 Jow, L. and Mukherjee, R. (1995) The human peroxisome proliferator-activated receptor (PPAR) subtype NUC1 represses the activation of hPPAR α and thyroid hormone receptors. *J. Biol. Chem.* **270**, 3836–3840
- 206 Webb, S. J., Xiao, G. H., Geoghegan, T. E. and Prough, R. A. (1996) Regulation of CYP4A expression in rat by dehydroepiandrosterone and thyroid hormone. *Mol. Pharmacol.* **49**, 276–287
- 207 Lee, S. S., Pineau, T., Drago, J., Lee, E. J., Owens, J. W., Kroetz, D. L., Fernandez-Salguero, P., Westphal, H. and Gonzalez, F. J. (1995) Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. *Mol. Cell. Biol.* **15**, 3012–3022
- 208 Peters, J. M., Zhou, Y. C., Ram, P. A., Lee, S. S., Gonzalez, F. J. and Waxman, D. J. (1996) Peroxisome proliferator-activated receptor α required for gene induction by dehydroepiandrosterone- β -sulfate. *Mol. Pharmacol.* **50**, 67–74
- 209 Palmer, C. N. A., Hsu, M. H., Muerhoff, A. S., Griffin, K. J. and Johnson, E. F. (1994) Interaction of the peroxisome proliferator-activated receptor α with the retinoid X receptor α unmasks a cryptic peroxisome proliferator response element. *J. Biol. Chem.* **269**, 18083–18089
- 210 Chambon, P. (1996) A decade of molecular biology of retinoic acid receptors. *FASEB J.* **10**, 940–954
- 211 Leo, M. A. and Lieber, C. S. (1985) New pathway for retinol metabolism in liver microsomes. *J. Biol. Chem.* **260**, 5228–5231
- 212 Zhang, Q. Y., Raner, G., Ding, X., Dunbar, D., Coon, M. J. and Kaminsky, L. S. (1998) Characterization of the cytochrome P450 CYP2J4: expression in rat small intestine and role in retinoic acid biotransformation from retinal. *Arch. Biochem. Biophys.* **353**, 257–264
- 213 Blumberg, B., Bolado, J., Derguini, F., Craig, A. G., Moreno, T., Chakravarti, D., Heyman, R. A., Buck, J. and Evans, R. M. (1996) Novel retinoic acid receptor ligands in *Xenopus* embryos. *Proc. Natl. Acad. Sci. U.S.A.* **93**, 4873–4878
- 214 Pijnappel, W. W. M., Folkers, G. E., de Jonge, W. J., Verdegem, P. J. E., de Laat, S. W., Lugtenburg, J., Hendriks, H. F. J., van der Saag, P. T. and Durston, A. J. (1998) Metabolism to a response pathway selective retinoid ligand during axial pattern formation. *Proc. Natl. Acad. Sci. U.S.A.* **95**, 15424–15429
- 215 White, J. A., Beckett-Jones, B., Guo, Y.-D., Dilworth, F. J., Bonasoro, J., Jones, G. and Petkovich, M. (1997) Identification of the retinoic acid-inducible all-*trans*-retinoic acid 4-hydroxylase. *J. Biol. Chem.* **272**, 18538–18541
- 216 Ray, W. J., Bain, G., Yao, M. and Gottlieb, D. I. (1997) *CYP26*, a novel mammalian cytochrome P450, is induced by retinoic acid and defines a new family. *J. Biol. Chem.* **272**, 18702–18708
- 217 Abu-Abed, S. S., Beckett, B. R., Chiba, H., Chithalen, J. V., Jones, G., Metzger, D., Chambon, P. and Petkovich, M. (1998) Mouse P450RAI (CYP26) expression and retinoic acid-inducible retinoic acid metabolism in F9 cells are regulated by retinoic acid receptor γ and retinoid X receptor α . *J. Biol. Chem.* **273**, 2409–2415
- 218 Leo, M. A., Iida, S. and Lieber, C. S. (1984) Retinoic acid metabolism by a system reconstituted with cytochrome P450. *Arch. Biochem. Biophys.* **234**, 305–312
- 219 Leo, M. A., Lasker, J. M., Raucy, J. L., Kim, C. I., Black, M. and Lieber, C. S. (1989) Metabolism of retinol and retinoic acid by human liver cytochrome P450IIC8. *Arch. Biochem. Biophys.* **269**, 305–312
- 220 Westin, S., Mode, A., Murray, M., Chen, R. and Gustafsson, J.-Å. (1993) Growth hormone and vitamin A induce P450C7 mRNA expression in primary rat hepatocytes. *Mol. Pharmacol.* **44**, 997–1002
- 221 Westin, S., Sonneveld, E., van der Leede, B. M., van der Saag, P. T., Gustafsson, J.-Å. and Mode, A. (1997) *CYP2C7* expression in rat liver and hepatocytes: regulation by retinoids. *Mol. Cell. Endocrinol.* **129**, 169–179
- 222 Carlberg, C. and Polly, P. (1998) Gene regulation by vitamin D₃. *Crit. Rev. Eukaryotic Gene Expression* **8**, 19–42
- 223 Umeson, K., Murakami, K. K., Thompson, C. C. and Evans, R. M. (1991) Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D₃ receptors. *Cell* **65**, 1255–1266
- 224 vom Baur, E., Zechel, C., Heery, D., Heine, M. J. S., Garnier, J. M., Vivat, V., Le Douarin, B., Gronemeyer, H., Chambon, P. and Losson, R. (1996) Differential ligand-dependent interactions between the AF-2 activating domain of nuclear receptors and the putative transcriptional intermediary factors mSUG1 and TIF1. *EMBO J.* **15**, 110–124
- 225 Alroy, I., Towers, T. L. and Freedman, L. P. (1995) Transcriptional repression of the interleukin-2 gene by vitamin D₃: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. *Mol. Cell. Biol.* **15**, 5789–5799
- 226 Carlberg, C. (1995) Mechanisms of nuclear signalling by vitamin D₃. Interplay with retinoid and thyroid hormone signalling. *Eur. J. Biochem.* **231**, 517–527
- 227 Schmeidlin-Ren, P., Thummel, K. E., Fisher, J. M., Paine, M. F., Lown, K. S. and Watkins, P. B. (1997) Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1 α ,25-dihydroxyvitamin D₃. *Mol. Pharmacol.* **51**, 741–754
- 228 Cali, J. J. and Russell, D. W. (1991) Characterization of human sterol 27-hydroxylase, a mitochondrial P450 that catalyzes multiple oxidation reactions in bile acid biosynthesis. *J. Biol. Chem.* **266**, 7774–7778
- 229 Axen, E., Postlind, H., Sjöberg, H. and Wikvall, K. (1994) Liver mitochondrial cytochrome P450 CYP27 and recombinant-expressed human CYP27 catalyze 1 α -hydroxylation of 25-hydroxyvitamin D₃. *Proc. Natl. Acad. Sci. U.S.A.* **91**, 10014–10018
- 230 Rosen, H., Reshef, A., Maeda, N., Lippoldt, A., Shpizen, S., Triger, L., Eggertsen, G., Björkhem, I. and Leitersdorf, E. (1998) Markedly reduced bile acid synthesis but maintained levels of cholesterol and vitamin D metabolites in mice with disrupted sterol 27-hydroxylase gene. *J. Biol. Chem.* **273**, 14805–14812
- 231 Postlind, H., Axen, E., Bergman, T. and Wikvall, K. (1997) Cloning, structure, and expression of a cDNA encoding vitamin D₃ 25-hydroxylase. *Biochem. Biophys. Res. Commun.* **241**, 491–497
- 232 Reinholz, G. G. and DeLuca, H. F. (1998) Inhibition of 25-hydroxyvitamin D₃ production by 1,25-dihydroxyvitamin D₃ in rats. *Arch. Biochem. Biophys.* **355**, 77–83
- 233 Takeyama, K., Kitanaka, S., Sato, T., Kobori, M., Yanagisawa, J. and Kato, S. (1997) 25-Hydroxyvitamin D₃ 1 α -hydroxylase and vitamin D synthesis. *Science* **277**, 1827–1830
- 234 Brenza, H. L., Kimmel-Jehan, C., Jehan, F., Shinki, T., Wakino, S., Anazawa, H., Suda, T. and DeLuca, H. F. (1998) Parathyroid hormone activation of the 25-hydroxyvitamin D₃ 1 α -hydroxylase gene promoter. *Proc. Natl. Acad. Sci. U.S.A.* **95**, 1387–1391
- 235 Kong, X. F., Zhu, X. H., Pei, Y. L., Jackson, D. M. and Holick, M. F. (1999) Molecular cloning, characterization, and promoter analysis of the human 25-hydroxyvitamin D₃ 1 α -hydroxylase gene. *Proc. Natl. Acad. Sci. U.S.A.* **96**, 6988–6993
- 236 Murayama, A., Takeyama, K., Kitanaka, S., Koder, Y., Hosoya, T. and Kato, S. (1998) The promoter of the human 25-hydroxyvitamin D₃ 1 α -hydroxylase gene confers positive and negative responsiveness to PTH, calcitonin, and 1 α ,25(OH)₂D₃. *Biochem. Biophys. Res. Commun.* **249**, 11–16
- 237 Ohyama, Y. and Okuda, K. (1991) Isolation and characterization of a cytochrome P-450 from rat kidney mitochondria that catalyzes the 24-hydroxylation of 25-hydroxyvitamin D₃. *J. Biol. Chem.* **266**, 8690–8695
- 238 Beckman, M., Talikonda, P., Werner, E., Prael, J. M., Yamada, S. and DeLuca, H. F. (1996) Human 25-hydroxyvitamin D₃ 24-hydroxylase, a multicatalytic enzyme. *Biochemistry* **35**, 8465–8472
- 239 St. Arnaud, R. (1999) Targeted inactivation of vitamin D hydroxylases in mice. *Bone* **25**, 127–129
- 240 Ohayama, Y., Ozono, K., Uchida, M., Shinki, T., Kato, S., Suda, T., Yamamoto, O., Noshiro, M. and Kato, Y. (1994) Identification of a vitamin D-responsive element in the 5'-flanking region of the rat 25-hydroxyvitamin D₃ 24-hydroxylase gene. *J. Biol. Chem.* **269**, 10545–10550
- 241 Chen, K. S. and DeLuca, H. F. (1995) Cloning of the human 1 α ,25-dihydroxyvitamin D₃ 24-hydroxylase gene promoter and identification of two vitamin D-responsive elements. *Biochim. Biophys. Acta* **1263**, 1–9

- 242 Zou, A., Elgort, M. G. and Allegretto, E. A. (1997) Retinoid X receptor (RXR) ligands activate the human 25-dihydroxyvitamin D₃ 24-hydroxylase promoter *via* RXR heterodimer binding to two vitamin D-responsive elements and elicit additive effects with 1,25-dihydroxyvitamin D₃. *J. Biol. Chem.* **272**, 19027–19034
- 243 Lee, Y.-F., Young, W.-J., Lin, W.-J., Shyr, C.-R. and Chang, C. (1999) Differential regulation of direct repeat 3 vitamin D₃ and direct repeat 4 thyroid hormone signaling pathways by the human TR4 orphan receptor. *J. Biol. Chem.* **274**, 16198–16205
- 244 Hanukoglu, I. (1992) Steroidogenic enzymes: structure, function, and role in regulation of steroid hormone biosynthesis. *J. Steroid Biochem. Mol. Biol.* **43**, 779–804
- 245 Stromstedt, M. and Waterman, M. R. (1995) Messenger RNAs encoding steroidogenic enzymes are expressed in rodent brain. *Brain Res. Mol. Brain Res.* **34**, 75–88
- 246 Keeney, D. S., Ikeda, Y., Waterman, M. R. and Parker, K. L. (1995) Cholesterol side-chain cleavage cytochrome P450 gene expression in the primitive gut of the mouse embryo does not require steroidogenic factor 1. *Mol. Endocrinol.* **9**, 1091–1098
- 247 Lala, D. S., Ikeda, Y., Luo, X., Baily, L. A., Meade, J. C. and Parker, K. L. (1995) A cell-specific nuclear receptor regulates the steroid hydroxylases. *Steroids* **60**, 10–14
- 248 Honda, S., Morohashi, K., Nomura, M., Takeya, H., Kitayama, M. and Omura, T. (1993) Ad4BP regulating steroidogenic P-450 gene is a member of steroid hormone receptor superfamily. *J. Biol. Chem.* **268**, 7494–7502
- 249 Morohashi, K., Honda, S., Inomata, Y., Handa, H. and Omura, T. (1992) A common *trans*-acting factor, Ad4-binding protein, to the promoters of steroidogenic P450s. *J. Biol. Chem.* **267**, 17913–17919
- 250 Honda, S., Morohashi, K. and Omura, T. (1990) Novel cAMP regulatory elements in the promoter region of bovine P-450(11 β) gene. *J. Biochem. (Tokyo)* **108**, 1042–1049
- 251 Lynch, J. P., Lala, D. S., Peluso, J. J., Luo, W., Parker, K. L. and White, B. L. (1993) Steroidogenic factor 1, an orphan receptor, regulates the expression of the rat aromatase gene in gonadal tissues. *Mol. Endocrinol.* **7**, 776–786
- 252 Bakke, M. and Lund, J. (1995) Mutually exclusive interactions of two nuclear orphan receptors determine activity of a cyclic adenosine 3',5'-monophosphate-responsive sequence in the bovine *CYP17* gene. *Mol. Endocrinol.* **9**, 327–339
- 253 Liu, Z. and Simpson, E. R. (1997) Steroidogenic factor 1 (SF-1) and Sp1 are required for regulation of bovine *CYP11A* gene expression in bovine luteal and adrenal Y1 cells. *Mol. Endocrinol.* **11**, 127–137
- 254 Chau, Y. M., Crawford, P. A., Woodson, K. G., Polish, J. A., Olson, L. M. and Sadvovsky, Y. (1997) Role of steroidogenic factor 1 in basal and 3',5'-cyclic adenosine monophosphate-mediated regulation of cytochrome P450 side-chain cleavage enzyme in the mouse. *Biol. Reprod.* **57**, 765–771
- 255 Luo, X., Ikeda, Y. and Parker, K. L. (1994) A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. *Cell* **77**, 481–490
- 256 Lala, D. S., Syka, P. M., Lazarchik, S. B., Mangelsdorf, D. J., Parker, K. L. and Heyman, R. A. (1995) Activation of the orphan nuclear receptor steroidogenic factor 1 by oxysterols. *Proc. Natl. Acad. Sci. U.S.A.* **94**, 4895–4900
- 257 Mellon, S. H. and Bair, S. R. (1998) 25-hydroxycholesterol is not a ligand for the orphan nuclear receptor steroidogenic factor-1 (SF-1). *Endocrinology (Baltimore)* **139**, 3026–3029
- 258 Christenson, L. K., McAllister, J. M., Martin, K. O., Javitt, N. B., Osborne, T. F. and Strauss, J. F. (1998) Oxysterol regulation of steroidogenic acute regulatory protein gene expression. Structural specificity and transcriptional and posttranscriptional actions. *J. Biol. Chem.* **273**, 30729–30735
- 259 Jacob, A. L. and Lund, J. (1998) Mutations in the activation function-2 core domain of steroidogenic factor-1 dominantly suppresses PKA-dependent transactivation of the bovine *CYP17* gene. *J. Biol. Chem.* **273**, 13391–13394
- 260 Liu, Z. and Simpson, E. R. (1999) Molecular mechanism for cooperation between Sp1 and steroidogenic factor-1 (SF-1) to regulate bovine *CYP11A* gene expression. *Mol. Cell. Endocrinol.* **153**, 183–196
- 261 Sadvovsky, Y., Crawford, P. A., Woodson, K. G., Polish, J. A., Clements, M. A., Tourtellotte, L. M., Simburger, K. and Milbrandt, J. (1995) Mice deficient in the orphan receptor steroidogenic factor 1 lack adrenal glands and gonads but express P450 side-chain cleavage enzyme in the placenta and have normal embryonic serum levels of corticosteroids. *Proc. Natl. Acad. Sci. U.S.A.* **92**, 10939–10943
- 262 Zhang, P. and Mellon, S. H. (1997) Multiple orphan nuclear receptors converge to regulate rat *P450c17* gene transcription: novel mechanisms for orphan nuclear receptor action. *Mol. Endocrinol.* **11**, 891–904
- 263 Yang, C., Zhou, C. and Chen, S. (1998) Modulation of aromatase expression in the breast tissue by ERR α 1 orphan receptor. *Cancer Res.* **58**, 5695–5700
- 264 Zhang, P., Hammer, F., Bair, S., Wang, J., Reeves, W. H. and Mellon, S. H. (1999) Ku autoimmune antigen is involved in placental regulation of rat *P450c17* gene transcription. *DNA Cell Biol.* **18**, 197–208
- 265 Mukai, K., Mitani, F., Shimada, H. and Ishimura, Y. (1995) Involvement of an AP-1 complex in zone-specific expression of the *CYP11B1* gene in the rat adrenal cortex. *Mol. Cell. Biol.* **15**, 6003–6012
- 266 Waterman, M. R. and Bischof, L. J. (1996) Mechanisms of ACTH (cAMP)-dependent transcription of adrenal steroid hydroxylases. *Endocr. Res.* **22**, 615–620
- 267 Michael, M. D., Kilgore, M. W., Morohashi, K. and Simpson, E. R. (1995) Ad4BP/SF-1 regulates cyclic AMP-induced transcription from the proximal promoter (PII) of the human aromatase P450 (*CYP19*) gene in the ovary. *J. Biol. Chem.* **270**, 13561–13566
- 268 Carlone, D. L. and Richards, J. S. (1997) Functional interactions, phosphorylation, and levels of 3',5'-cyclic adenosine monophosphate-regulatory element binding protein and steroidogenic factor-1 mediate hormone-regulated and constitutive expression of aromatase in gonadal cells. *Mol. Endocrinol.* **11**, 292–304
- 269 Ahlgren, R., Suske, G., Waterman, M. R. and Lund, J. (1999) Role of Sp1 in cAMP-dependent transcriptional regulation of the bovine *CYP11A* gene. *J. Biol. Chem.* **274**, 19422–19428
- 270 Kagawa, N. and Waterman, M. R. (1992) Purification and characterization of a transcription factor which appears to regulate cAMP responsiveness of the human *CYP21B* gene. *J. Biol. Chem.* **267**, 25213–25219
- 271 Nomura, M., Kawabe, K., Matsushita, S., Oka, S., Hatano, O., Harada, N., Nawata, H. and Morohashi, K. (1998) Adrenocortical and gonadal expression of the mammalian *Fz-F1* gene encoding Ad4BP/SF-1 is independent of pituitary control. *J. Biochem. (Tokyo)* **124**, 217–224
- 272 Brown, M. S. and Goldstein, J. L. (1997) The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. *Cell* **89**, 331–340
- 273 Rozman, D., Stromstedt, M., Tsui, L. C., Scherer, S. W. and Waterman, M. R. (1996) Structure and mapping of the human lanosterol 14 α -demethylase gene (*CYP57*) encoding the cytochrome P450 involved in cholesterol biosynthesis: comparison of exon/intron organization with other mammalian and fungal *CYP* genes. *Genomics* **38**, 371–381
- 274 Stromstedt, M., Waterman, M. R., Haugen, T. B., Tasken, K., Parvinen, M. and Rozman, D. (1998) Elevated expression of lanosterol 14 α -demethylase (*CYP57*) and the synthesis of oocyte meiosis-activating sterols in postmeiotic germ cells of male rats. *Endocrinology (Baltimore)* **139**, 2314–2321
- 275 Janowski, B. A., Willy, P. J., Devi, T. R., Falck, J. R. and Mangelsdorf, D. J. (1996) An oxysterol signalling pathway mediated by the nuclear receptor LXR α . *Nature (London)* **383**, 728–731
- 276 Stromstedt, M., Rozman, D. and Waterman, M. R. (1996) The ubiquitously expressed human *CYP57* encodes lanosterol 14 α -demethylase, a cytochrome P450 whose expression is regulated by oxysterols. *Arch. Biochem. Biophys.* **329**, 73–81
- 277 Yoshida, Y., Yamashita, C., Noshiro, M., Fukuda, M. and Aoyama, Y. (1996) Sterol 14-demethylase P450 activity expressed in rat gonads: contribution to the formation of mammalian meiosis-activating sterol. *Biochem. Biophys. Res. Commun.* **223**, 534–538
- 278 Russell, D. W. and Setchell, K. D. R. (1992) Bile acid biosynthesis. *Biochemistry* **31**, 4737–4749
- 279 Noshiro, M., Nishimoto, M., Morohashi, K. and Okuda, K. (1989) Molecular cloning of cDNA for cholesterol 7 α -hydroxylase from rat liver microsomes. Nucleotide sequence and expression. *FEBS Lett.* **257**, 97–100
- 280 Russell, D. W. (1999) Nuclear orphan receptors control cholesterol catabolism. *Cell* **97**, 539–542
- 281 Rose, K. A., Stapleton, G., Dott, K., Kieny, M. P., Best, R., Schwarz, M., Russell, D. W., Björkhem, I., Seckl, J. and Lathé, R. (1997) *Cyp7b*, a novel brain cytochrome P450, catalyzes the synthesis of neurosteroids 7 α -hydroxydehydroepiandrosterone and 7 α -hydroxypregnenolone. *Proc. Natl. Acad. Sci. U.S.A.* **94**, 4925–4930
- 282 Schwarz, M., Lund, E. G., Lathé, R., Björkhem, I. and Russell, D. W. (1997) Identification and characterization of a mouse oxysterol 7 α -hydroxylase cDNA. *J. Biol. Chem.* **272**, 23995–24001
- 283 Lund, E. G., Guileyardo, J. M. and Russell, D. W. (1999) cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. *Proc. Natl. Acad. Sci. U.S.A.* **96**, 7238–7243
- 284 Lund, E. G., Kerr, T. A., Sakai, J., Li, W.-P. and Russell, D. W. (1998) cDNA cloning of mouse and human cholesterol 25-hydroxylases, polytopic membrane proteins that synthesize a potent oxysterol regulator of lipid metabolism. *J. Biol. Chem.* **273**, 34316–34318
- 285 Lehmann, J. M., Kliewer, S. A., Moore, L. B., Smith-Oliver, T. A., Oliver, B. B., Su, J.-L., Sundseth, S. S., Winegar, D. A., Blanchard, D. E., Spencer, T. A. and Willson, T. M. (1997) Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. *J. Biol. Chem.* **272**, 3137–3140
- 286 Stroup, D., Crestani, M. and Chiang, J. Y. L. (1997) Identification of a bile acid response element in the cholesterol 7 α -hydroxylase gene *CYP7A*. *Am. J. Physiol.* **273**, G508–G517

- 287 Peet, D. J., Turley, S. D., Ma, W., Janowski, B. A., Lobaccaro, J.-M. A., Hammer, R. E. and Mangelsdorf, D. J. (1998) Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR α . *Cell* **93**, 693–704
- 288 Nitta, M., Ku, S., Brown, C., Okamoto, A. Y. and Shan, B. (1999) CPF: An orphan nuclear receptor that regulates liver-specific expression of the human cholesterol 7 α -hydroxylase gene. *Proc. Natl. Acad. Sci. U.S.A.* **96**, 6660–6665
- 289 Wang, H., Chen, J., Hollister, K., Sowers, L. C. and Forman, B. M. (1999) Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. *Mol. Cell* **3**, 543–553
- 290 Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D. and Lehmann, J. M. (1999) Bile acids: natural ligands for an orphan nuclear receptor. *Science* **284**, 1365–1368
- 291 Forman, B. M., Goode, E., Chen, J., Oro, A. E., Bradley, D. J., Perlmann, T., Noonan, D. J., Burka, L. T., McMorris, T., Kozak, C. A., Lamph, W. W., Evans, R. M. and Weinberger, C. (1995) Identification of a nuclear receptor that is activated by farnesol metabolites. *Cell* **81**, 687–693
- 292 Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J. and Shan, B. (1999) Identification of a nuclear receptor for bile acids. *Science* **284**, 1362–1365
- 293 Stroup, D., Crestani, M. and Chiang, J. Y. L. (1997) Orphan receptors chicken ovalbumin upstream promoter transcription factor II (COUP-TFII) and retinoid X receptor (RXR) activate and bind the rat cholesterol 7 α -hydroxylase gene (*CYP7A*). *J. Biol. Chem.* **272**, 9833–9839
- 294 Pikuleva, I. A., Babiker, A., Waterman, M. R. and Björkhem, I. (1998) Activities of recombinant human cytochrome P450c27 (*CYP27*) which produce intermediates of alternative bile acid biosynthetic pathways. *J. Biol. Chem.* **273**, 18153–18160
- 295 Xu, G., Salen, G., Shefer, S., Tint, G. S., Nguyen, L. B., Chen, T. S. and Greenblatt, D. (1999) Increasing dietary cholesterol induces different regulation of classic and alternative bile acid synthesis. *J. Clin. Invest.* **103**, 89–95
- 296 Twisk, J., de Wit, E. C. and Princen, H. M. (1995) Suppression of sterol 27-hydroxylase mRNA and transcriptional activity by bile acids in cultured rat hepatocytes. *Biochem. J.* **305**, 505–511
- 297 Stravitz, R. T., Vlahcevic, Z. R., Russell, T. L., Heizer, M. L., Avadhani, N. G. and Hylemon, P. B. (1996) Regulation of sterol 27-hydroxylase and an alternative pathway of bile acid biosynthesis in primary cultures of rat hepatocytes. *J. Steroid Biochem. Mol. Biol.* **57**, 337–347
- 298 Björkhem, I., Diczfalusy, U. and Lutjohann, D. (1999) Removal of cholesterol from extrahepatic sources by oxidative mechanisms. *Curr. Opin. Lipidol.* **10**, 161–165
- 299 Andersson, U., Yang, Y.-Z., Björkhem, I., Einarsson, C., Eggertsen, G. and Gåfvels, M. (1999) Thyroid hormone suppresses hepatic sterol 12 α -hydroxylase (*CYP8B1*) activity and messenger ribonucleic acid in rat liver: failure to define known thyroid response elements in the gene. *Biochim. Biophys. Acta* **1438**, 167–184
- 300 Ishida, H., Kuruta, Y., Gotoh, O., Yamashita, C., Yoshida, Y. and Noshiro, M. (1999) Structure, evolution, and liver-specific expression of sterol 12 α -hydroxylase P450 (*CYP8B*). *J. Biochem. (Tokyo)* **126**, 19–25
- 301 Li, H. C., Dehai, S. S. and Kupfer, D. (1995) Induction of the hepatic *CYP2B* and *CYP3A* enzymes by the proestrogenic pesticide methoxychlor and by DDT in the rat. Effects on methoxychlor metabolism. *J. Biochem. Toxicol.* **10**, 51–61
- 302 Honkakoski, P. and Negishi, M. (1997) The structure, function, and regulation of cytochrome P450 2A enzymes. *Drug Metab. Rev.* **29**, 977–996
- 303 Stresser, D. M. and Kupfer, D. (1998) Human cytochrome P450-catalyzed conversion of the proestrogenic pesticide methoxychlor into an estrogen. Role of *CYP2C19* and *CYP1A2* in O-demethylation. *Drug. Metab. Dispos.* **26**, 868–874